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Abstract: Throughout much of life, women have lower blood pressures than men. 
However, after menopause, women’s blood pressures surpass that of men, suggesting that 
estrogen plays a role in preventing hypertension. The low salt diet is a first line treatment 
for hypertension, but it is a difficult diet to maintain. Patients may alternate between 
periods of high and low salt intake, essentially “yo-yo” dieting. The effects of this are 
unknown, particularly in females. Additionally, it is unclear if any effects may be altered 
by the presence or absence of estrogen. Our goals were to determine the alterations in salt 
intake and body fluid hormones that occur with repeated dietary sodium deprivations. 
Using ovariectomized rats with (EB) and without (OIL) estrogen treatment, we subjected 
rats to one or two dietary sodium deprivations using low salt laboratory chow. 0.5 M 
NaCl and water intakes were recorded after each period of regular chow or deprivation. 
After deprivation, rats were sacrificed, and trunk blood was collected for analysis of 
vasopressin, norepinephrine, epinephrine, and aldosterone content. Plasma sodium 
concentration, plasma protein concentration, body weight, and uterine weight were also 
measured. There was no difference in the salt intakes of OIL- or EB-treated rats after one 
or two dietary sodium deprivations. However, EB-treated rats drank a less concentrated 
solution overall, suggesting less overcompensation after dietary sodium deprivation. 
Additionally, after a single episode of dietary sodium deprivation, EB-treated rats’ 
consumption remained elevated above baseline even after returning to regular laboratory 
chow. These behavioral differences were not explained by alterations in vasopressin, 
norepinephrine, epinephrine, or aldosterone. Plasma sodium and plasma protein 
concentrations also did not show alterations related to the change in behavior. Further 
research is necessary to determine the mechanism behind these changes in intake in EB-
treated rats, which may ultimately be clinically relevant for both pre- and postmenopausal 





TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION ..................................................................................................... 1 
 
 
II. REVIEW OF LITERATURE ................................................................................... 5 
  
 2.1 Overview: Hypertension & Low Salt Diet ........................................................ 5 
    2.1.1 Hypertension ............................................................................................... 5 
    2.1.2 Salt Sensitivity ............................................................................................ 7 
 2.2 Integrative Body Fluid Regulation .................................................................. 10 
    2.2.1 Physiology of Body Fluid and Blood Pressure Control ............................ 10 
    2.2.2 Hormones of Body Fluid Regulation ........................................................ 11 
       2.2.2a Vasopressin .......................................................................................... 11 
       2.2.2b Norepinephrine and Epinephrine ......................................................... 14 
       2.2.2c Aldosterone .......................................................................................... 16 
    2.2.3 Salt Intake & Behavior in Animal Models ............................................... 17 
 2.3 Estrogen & Body Fluid Regulation ................................................................. 19 
    2.3.1 Mechanism of Estrogen Actions ............................................................... 19 
    2.3.2 Estrogen Effects on Physiology of Body Fluid & Blood Pressure Control21 
    2.3.3 Estrogen Effects on Hormones of Body Fluid Regulation ....................... 21 
       2.3.3a Vasopressin .......................................................................................... 21 
       2.3.3b Norepinephrine and Epinephrine ......................................................... 23 
       2.3.3c Aldosterone .......................................................................................... 24 
    2.3.4 Estrogen Effects on Salt Intake ................................................................. 25 
 
 
III. METHODOLOGY ............................................................................................... 29 
 
 3.1 General Methods ............................................................................................. 29 
    3.1.1 Animals, Ovariectomy, Hormone Replacement ....................................... 29 
 3.2 Single Sodium Deprivation Protocol .............................................................. 30 
    3.2.1 Testing ....................................................................................................... 30 
    3.2.2 Plasma Hormone Levels ........................................................................... 31 
 3.3 Repeated Sodium Deprivation Protocol .......................................................... 32 
    3.3.1 Testing ....................................................................................................... 32 
    3.3.2 Plasma Hormone Levels ........................................................................... 34 
 3.4 Verification of Estrogen Treatment and Sodium-Deficient Diet Effectiveness .  
 ............................................................................................................................... 35 
vii 
 
Chapter          Page 
 
    3.4.1 Body Weights ............................................................................................ 35 
    3.4.2 Uterine Weights ........................................................................................ 35 
    3.4.3 Plasma Protein Concentration ................................................................... 35 
    3.4.4 Plasma Sodium Concentration .................................................................. 35 
 3.5 Statistics .......................................................................................................... 35 
    3.5.1 Verification of Estrogen Treatment and Sodium-Deficient Diet Effectiveness
 ............................................................................................................................... 36 
    3.5.2 Salt and Water Intakes .............................................................................. 36 
       3.5.2a Baseline Intakes ................................................................................... 36 
       3.5.2b Stimulated and Unstimulated Intakes after Repeated Dietary Sodium 
Deprivation ........................................................................................................... 37 
        3.5.2c Test Day Intakes .................................................................................. 37 
    3.5.3 Plasma Hormone Levels ........................................................................... 37 
 
IV. FINDINGS ............................................................................................................ 39 
 
 4.1 Verification of Estrogen Treatment and Sodium-Deficient Diet Effectiveness   
 ............................................................................................................................... 39 
    4.1.1 Body Weights ............................................................................................ 39 
    4.1.2 Uterine Weights ........................................................................................ 43 
    4.1.3 Plasma Protein Concentration ................................................................... 45 
    4.1.4 Plasma Sodium Concentration .................................................................. 46 
 4.2 Salt and Water Intakes .................................................................................... 47 
    4.2.1 Baseline Intakes ........................................................................................ 47 
    4.2.2 Stimulated and Unstimulated Intakes after Repeated Dietary Sodium 
Deprivation ........................................................................................................... 48 
    4.2.3 Test Day Intakes ....................................................................................... 51 
 4.3 Plasma Hormone Levels ................................................................................. 54 
 
V.  CONCLUSION ..................................................................................................... 58 
 
 5.1 Aim 1: Behavioral Changes ............................................................................ 58 
    5.1.1 Unstimulated Intake .................................................................................. 58 
    5.1.2 Stimulated Intakes ..................................................................................... 59 
 5.2 Aim 2: Physiological Changes Part 1: Body Weight, Uterine Weight, Plasma 
Protein, and Plasma Sodium ................................................................................. 61 
  5.2.1 Body Weight .......................................................................................... 61 
  5.2.2 Uterine Weights ..................................................................................... 62 
  5.2.3 Plasma Protein Concentration ................................................................ 62 
  5.2.4 Plasma Sodium Concentration ............................................................... 63 
 5.3 Aim 2: Physiological Changes Part 2: Body Fluid Hormones ....................... 63 
  5.3.1 Vasopressin Concentration .................................................................... 63 
  5.3.2 Norepinephrine and Epinephrine Concentration ................................... 65 
  5.3.3 Aldosterone Concentration .................................................................... 66 
viii 
 
Chapter          Page 
 5.4 Behavioral and Physiological Integration ....................................................... 67 
 5.5 Clinical Implications ....................................................................................... 72 
 




LIST OF TABLES 
 
 
Table           Page 
 
   1 Summary of the single deprivation experimental groups ..................................... 32 
   2 Summary of the repeated deprivation experimental groups  ................................ 34 
   3 Change in body weight, single dietary sodium deprivation .................................. 41 
   4 Change in body weight, repeated dietary sodium deprivation .............................. 42 
   5 Comparison of plasma hormone levels to sCon ................................................... 69
x 
 
LIST OF FIGURES 
 
Figure           Page 
 
   1 Timeline for single sodium deprivation protocol .................................................. 31 
   2 Timeline for repeated sodium deprivation protocol .............................................. 34 
   3 Raw body weights, single deprivation .................................................................. 40 
   4  Raw body weights, repeated deprivation ............................................................. 40 
   5 Uterine weights of OIL- and EB-treated rats ........................................................ 44 
   6 Plasma protein concentration in OIL- and EB-treated rats ................................... 45 
   7 Plasma sodium concentration in OIL- and EB-treated rats .................................. 46 
   8 Baseline salt intakes by OIL- and EB-treated rats in the single dietary sodium 
deprivation protocol ............................................................................................ 47 
   9 Baseline water intakes by OIL- and EB-treated rats in the single dietary sodium 
deprivation protocol ............................................................................................ 48 
   10 Salt intakes by OIL- and EB-treated rats during the repeated dietary sodium 
deprivation protocol ............................................................................................ 49 
   11 Water intakes by OIL- and EB-treated rats during the repeated dietary sodium 
deprivation protocol ............................................................................................ 50 
   12 Test day salt intakes by OIL- and EB-treated rats in the single and repeated dietary 
sodium deprivation protocols .............................................................................. 51 
   13 Test day water intakes by OIL- and EB-treated rats in the single and repeated dietary 
sodium deprivation protocols .............................................................................. 52 
   14 Concentration of fluid consumed on test day by OIL- and EB-treated rats in the 
single and repeated dietary sodium deprivation protocols .................................. 53 
   15 Plasma norepinephrine concentrations for OIL- and EB-treated rats ................. 54 
   16 Plasma epinephrine concentrations for OIL- and EB-treated rats ...................... 55 
   17 Plasma vasopressin concentrations for OIL- and EB-treated rats  ..................... 56 
   18 Plasma aldosterone concentrations for OIL- and EB-treated rats  ...................... 57 







 Diagnoses of hypertension have increased over time, contributing to health consequences 
such as heart failure and renal injury (Lim et al., 2012). It is estimated that by 2030, hypertension will 
have grown 7.2% from the 2013 estimates (Go et al., 2013). It has become clear that blood pressure 
and hypertension are sexually dimorphic. While men have higher blood pressure throughout much of 
life, women’s blood pressure increases after menopause (Reckelhoff, 2001; August & Oparil et al., 
1999). Inexplicably, research into the mechanisms for these sex differences is lacking, despite the fact 
that women are at a greater risk of hypertension-related cardiovascular problems (Rosamond, 2007). 
The loss of ovarian hormones after menopause suggests estrogen may have a protective role against 
cardiovascular events, including hypertension. The mechanisms behind this remain to be determined. 
Given the aging population, better understanding of the control of blood pressure is critical to address 
this health problem. 
Typically, hypertension is first treated with lifestyle changes, including adhering to a low salt 
diet. For some “salt-sensitive” individuals, blood pressure can fluctuate in relation to their salt intake 
(Weinberger et al., 1986). However, the low salt diet is difficult to maintain. Thus, patients may 
alternate between periods of high and low salt consumption, essentially “yo-yo” dieting. Home health 
visits, public education, and support of family members have limited success in increasing 
compliance to the diet (Cohen et al., 1991; Pietenin et al., 1984; Staessen et al., 1988). We are not 
aware of any studies that examined the possibility of long-term effects of yo-yo salt dieting, as could
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occur in noncompliant human patients. 
In contrast, a wealth of information about sodium depletion is available from animal studies, 
particularly about the behavioral consequences of sodium depletion. Repeated pharmacological 
treatments that deplete body sodium change the drinking behavior of rats, such that male rats drink 
increasingly more salt both during and between repeated furosemide-induced depletions, despite no 
greater sodium loss (Sakai et al., 1989). Similar effects in male rats have been seen using 
transperitoneal dialysis (Falk et al., 1966). Female rats tend to have higher salt intake than males in 
baseline conditions (i.e. with no manipulations of body sodium; Leshem et al., 2004), which persists 
in the period between multiple depletions. 
However, the reasons for these behavioral differences are unclear. Sex-related changes in 
various body fluid hormones may be responsible. For example, it is known that vasopressin, an 
important hormone for controlling sodium and water balance via the kidneys, is influenced by salt 
intake (Ludwig et al., 1996), and may also play a role in salt appetite (Flynn 2002). The 
catecholamines epinephrine and norepinephrine are involved in vasoconstriction, kidney-mediated 
fluid balance, and are also altered by salt intake (Romoff et al., 1979). Additionally, aldosterone, 
which also affects the retention of salt in the kidneys, is increased by sodium depletion and decreased 
by salt consumption (Hall, 2015), but aldosterone is unchanged by multiple depletions despite 
increasing salt intake (Sakai et al., 1989). High doses of aldosterone also have been shown to increase 
salt intake in rats (Rice & Richter, 1943). 
The difference in salt intake in males and females may be explained by these hormones, but 
the effects of estrogen on them require further study. Studies show conflicting results, with reports of 
an increase in baseline vasopressin with estrogen (Skowsky et al., 1979), or no change (Crofton et al., 
1985). Similarly, norepinephrine’s effects are reported to be augmented by estradiol treatment 
(Colucci et al., 1982), but acute injection of estradiol has no effect on the response to phenylephrine 
3 
 
(He et al., 1998). Estrogen treatment decreases aldosterone levels in the zona glomerulosa (Macova et 
al., 2008), but studies in humans have shown increases (Crane and Harris, 1969) or no change (Seely 
et al., 1999) in aldosterone with estrogen treatment. Any of these hormones may be playing a role in 
the observed sex differences in salt intake and the possible consequences for blood pressure control, 
but conflicting findings complicate our understanding and should be explored further.  
Despite the knowledge gained from research in this field, there are still gaps in the literature. 
At present, the effects of estrogen on behavioral and physiological responses to repeated sodium 
deficiencies has yet to be elucidated. With few exceptions, studies examining repeated depletions 
have used only males. Studies that use both males and females are conflicted as to whether it is 
estrogen or testosterone responsible for the sex differences in intakes, with both testosterone (Chow et 
al., 1992) and estrogen (Scheidler et al., 1994) treatments causing decreases in stimulated salt intakes. 
More critically, few studies have used solely a low salt diet to induce sodium deficiency, as most use 
furosemide depletions (Sakai et al., 1987; Sakai et al., 1989; Leshem et al., 2004; Na et al., 2007) or a 
combination of furosemide and sodium deficient chow (Chow et al., 1992; Roitman et al., 2002). 
These studies focused on the behavioral consequences; thus, it is yet to be established whether 
vasopressin, norepinephrine, epinephrine, or aldosterone may be responsible for the observed sex 
differences in the responses to repeated deprivations.  
Thus, we hypothesized that estrogen alters behavioral and hormonal responses during 
repeated episodes of NaD. This dissertation tested this hypothesis, addressing these specific aims: 
Aim 1: Behavioral effects of repeated dietary sodium deficiency (rNaD) on female rats with and 
without estrogen. I will analyze salt and fluid intake to test the hypothesis that estrogen status changes 




Aim 2: Physiological effects of repeated dietary sodium deficiency (rNaD) on female rats with and 
without estrogen. I will use ELISA to measure plasma levels of vasopressin, catecholamines, and 
aldosterone, as well as using an ion selective electrode to measure plasma sodium, to test the 
hypothesis that estrogen status alters hormone concentrations and plasma sodium levels during 






REVIEW OF THE LITERATURE 
2.1 Overview: Hypertension & Low Salt Diet 
2.1.1 Hypertension  
 Hypertension has been increasing in recent years. 36% of Americans currently have 
hypertension, defined by the American Heart Association as blood pressure in excess of 130/80 
(Whelton et al., 2018). In 2010, hypertension was listed as the leading cause of death and 
“disability-adjusted life years,” or the number of years of life lost due to disability (Lim et al., 
2012). Research from the American Heart Association predicts that by 2030 hypertension 
prevalence will increase 7.2% from the 2013 estimates (Go et al., 2013). Chronically elevated 
blood pressure can put a strain on numerous physiological systems. Patients with hypertension are 
more likely to have strokes, heart attacks, kidney injury, and other health consequences (Kotchen, 
2018). Additionally, those who have high blood pressure are more likely to have comorbidities 
such as heart failure, cardiovascular disease, renal injury, diabetes, and obesity (Kotchen, 2018; 
Lim et al., 2012). Overall, it is estimated that hypertensive patients account for $131 billion more 
in healthcare costs than non-hypertensive patients  (Kirkland et al., 2018). 
 While more research is necessary to address the public health crisis of hypertension, it is 
well known that blood pressure is sexually dimorphic (Crofton and Share, 1997; Khoury et al., 
1992; Wiinberg et al., 1995). However, many of the studies performed on blood pressure and 
body fluid hormones have only included males (Cowley et al., 1981; Esler  et al., 1977; Mohring 
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et al., 1977; Sakai et al., 1986; Sakai et al., 1987; Spielman and Davis, 1974). Regardless, 
research that has been performed on both sexes has provided valuable information. Before 
puberty, blood pressures in males and females are similar (Jackson et al., 2007; Rowland and 
Roberts, 1982). Throughout much of life, women have lower 24-hour ambulatory blood pressures 
than men (Khoury et al., 1992; Wiinberg et al., 1995); however, women’s blood pressure 
increases after menopause, eventually surpassing men’s (August & Oparil, 1999; Reckelhoff, 
2001). A large cross-sectional study found that older women had significantly higher systolic and 
diastolic blood pressures regardless of smoking status, which was a possible confounding factor 
(Zanchetti, 2005). This study also stratified participants by age to reduce the blood pressure 
differences attributable to aging alone and found that while age influenced blood pressure 
independent of other factors, menopause was also an independent risk factor for increased blood 
pressure. Studies vary on the reported age at which women’s blood pressure surpasses that of 
men, probably due to the varying age range at which individual women experience and complete 
menopause. Some report that age-matched men have higher 24-hour mean blood pressures until 
age 70 (Wiinberg et al., 1995), while others find that after 50 the incidence of hypertension 
increases in women (Hay et al., 2016). As shown, research has increasingly turned to studying 
hypertension in women, but this is still an area lacking in important research. It is imperative to 
expand this field, especially due to the increased risk of hypertension-related cardiovascular 
events in postmenopausal women compared to age-matched premenopausal women (Rosamond 
et al., 2007). 
Sexual dimorphism related to hypertension is evident in animal studies as well. Multiple 
studies in different rat strains have shown higher blood pressures in males than in females 
(Crofton et al., 1993; Hinojosa-Laborde et al., 2000; Masubuchi et al., 1982). Research has 
pointed to estrogen playing a role in this dimorphism, but conflicting findings of the effect of 
estrogen have been reported. For example, when estrogen levels fall after menopause, blood 
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pressure increases (Staessen et al., 1989). Conflicting evidence for the use of hormone 
replacement therapy in postmenopausal women to decrease blood pressure has been reported. 
Some studies have found no benefit of oral hormone replacement therapy (Akkad et al., 1997), or 
a benefit only at certain times of day (Seely et al., 1999), while animal studies have found that 
administration of estrogen reverses hypertension (Crofton and Share, 1997). Clearly, estrogen’s 
influence on many areas involved in body fluid control remains to be fully examined. 
2.1.2 Salt Sensitivity 
 Treatment for hypertension includes medications such as thiazides, calcium channel 
blockers, and ACE inhibitors (James et al., 2014). However, lifestyle changes have increasingly 
been shown to provide benefit for many patients. These changes include exercising, losing 
weight, and decreasing salt intake. Salt consumption was first theorized to be a possible 
contributing factor to some health conditions in 1901 (DiNicolantonio and O’Keefe, 2017). As 
summarized in He and MacGregor’s review (2002), in 1904, Ambard and Beaujard were the first 
to show a reduction in blood pressure through salt restriction in kidney disease patients. But in 
1948, Kempner was the first to show a benefit of reducing salt specifically in hypertensive 
patients, though the diet proposed a salt restriction far beyond today’s suggested amounts 
(Kempner, 1948). Since then, many studies have supported moderate reduction of dietary sodium 
for improving the blood pressure of the general population, even in normotensive patients (for 
review, see He and MacGregor 2010). One particularly successful intervention study performed 
in Portugal had participants lower salt intake but left the amount up to participants, and ultimately 
saw a 47% reduction in salt intake and a decrease in systolic blood pressure of 5.0 mmHg and in 
diastolic blood pressure of 5.1 mmHg after 2 years (Forte et al., 1989). Currently, JNC 8, the 
blood pressure management consensus guidelines, recommends that patients aiming for the “low 
salt diet” consume at most 2400 mg/day, but ideally even less (Arnette et al., 2019). Despite these 
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studies, Americans consume far more than the recommended amount of salt. The average 
American over the age of 2 consumes 3400 mg/day of salt (“What We Eat in America”).  
 Despite the consequences of hypertension, many patients do not have it controlled. The 
CDC reported that, in 2015-2016, 30.2% of adults over 20 years of age had hypertension, and 
59.7% of those patients were uncontrolled regardless of which intervention was employed (Fryar 
et al., 2017). For the low salt diet, controlling hypertension is particularly problematic. Patients 
advised to adhere to a low salt diet will often alternate between low and high consumptions of 
salt, essentially “yo-yo” salt dieting. This struggle with compliance has been shown in many 
intervention studies. For example, the North Karelia Project in Finland, which aimed to lower salt 
intake in the general population, used several methods including direct-to-patient nutrition 
education, press, and radio (Pietinen et al., 1984). A line of low salt products and a new mineral 
salt without sodium were released as well. After three years, the authors found that salt intake had 
not changed overall, and normotensive patients were more likely to have changed habits than 
hypertensive patients. Another intervention project used positive feedback through urine sodium 
monitoring to help their hypertensive subjects lower salt intake (Weinberger et al., 1988). Despite 
feedback, fewer than half of the patients were compliant with the diet by the authors’ definition of 
a urinary sodium excretion of 80 mmol/day. Later studies recruited a household member to also 
go on the low salt diet, but this made no difference in compliance compared to instructing only 
the patient to change their diet (Cohen et al., 1991). These and many other studies indicate how 
difficult it can be for patients to maintain the low salt diet. Given how common such 
noncompliance is, it is crucial to understand the changes that happen with noncompliance in order 
to better educate patients and help healthcare providers make informed clinical decisions. Further 
research is necessary to determine what, if any, physiological or behavioral consequences occur 
with yo-yo salt dieting.  
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Though CDC recommends everyone lower their salt intake, some people are more 
sensitive to changes in dietary salt than others, a phenomenon termed salt sensitivity. However, 
results from studies on salt sensitivity vary widely depending on the duration of study and the 
amount of salt in the diets. Nevertheless, a meta-analysis of trials greater than a month in length 
supported a reduction in salt intake for both normotensive and hypertensive patients for the 
purpose of reducing blood pressure (He and MacGregor, 2002). This blood pressure reduction 
was predicted to reduce deaths from strokes and coronary events for both patient groups, which 
would also reduce healthcare costs and the burden on the healthcare system due to these 
complications.  
 While there are many studies on salt sensitivity in both humans and animals, the 
definition of salt sensitivity differs from study to study. For example, one paper defined it as more 
than a 10% increase in blood pressure when changing from a low salt diet to a high salt diet 
(Kawasaki et al. 1978), while another defined it as a decrease in 10 mm Hg in systolic blood 
pressure when salt depleted compared to salt loaded (Schulman et al., 2006). There are many 
other definitions, the discussion of which is beyond the scope of this dissertation. Researchers 
have struggled to determine the exact mechanisms of salt sensitivity. A study by Kawasaki et al. 
(1978) found that patients who were salt resistant excreted more sodium and gained less weight 
when on a high salt diet than salt sensitive patients did. However, what is clear is that salt 
sensitivity is sexually dimorphic. 
 The decrease in ovarian hormones that occurs during and after menopause does appear to 
be an independent risk factor for development of salt sensitivity, which may predispose women to 
develop hypertension. In support of this, Schulman et al. (2006) found that premenopausal 
women who underwent hysterectomy and ovariectomy were at risk of developing salt sensitivity 
four months post-surgery. In contrast, their baseline blood pressures did not increase in that time 
frame, indicating that the postmenopausal elevation takes longer than the time frame of this study. 
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However, it can take 5-20 years after menopause to develop elevations in blood pressure, so this 
result would not be surprising (Reckelhoff, 2001). Another study showed increased salt 
sensitivity in postmenopausal women compared to premenopausal women (Pechere-Bertschi, 
2004). This study used dietary restriction, whereas the study by Schulman et al. used furosemide 
and saline for restriction and salt loading. With both methods, there is evidence that menopause 
and, therefore estrogen, may play a role in salt sensitivity. Additionally, animal studies have 
shown that salt sensitivity may increase in some rat strains after ovariectomy, as studies have 
found alterations in salt responsiveness in Dahl salt-sensitive rats (Zheng et al., 2008) and in 
spontaneously hypertensive rats (Fang et al., 2001).  
While this sexual dimorphism is likely multifactorial, many theories have surfaced as to 
the causes. Reproductive steroid hormones like estrogen and testosterone are the primary 
suspects, with many studies attempting to identify how each affects blood pressure. Estrogen 
modulation of body fluid hormones likely occurs, but it is unclear what aspects of body fluid 
control are involved. The mechanisms of sex-related changes in animals or humans have yet to be 
elucidated. My goal is to address these gaps in our knowledge by investigating how estrogen 
alters physiological control of body fluid regulation during repeated episodes of dietary sodium 
deprivation. 
 
2.2 Integrative Body Fluid Regulation 
2.2.1 Physiology of Body Fluid and Blood Pressure Control 
 At its simplest, blood pressure is a function of body fluid control. Research in body fluid 
control can give insights into clinical applications such as blood pressure. Osmolarity of body 
fluid is tightly controlled, as it is important for optimal cellular functioning. The body fluid 
compartments include the intracellular space—which mostly contains the ions potassium and 
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phosphate—as well as the extracellular space (G&H Ch 25). The extracellular space is further 
divided into the interstitial fluid and plasma. These compartments contain much of the sodium 
found in the body. Sodium is the most important ion in the extracellular fluid, as water will 
quickly follow it through osmotic movement. In order to maintain homeostasis of all of these 
spaces, input of fluid through eating and drinking must be the same as the output. The body is 
finely tuned to keep osmolarity relatively constant. Too low of sodium concentration, or 
hyponatremia, can result in consequences such as hyponatremic encephalopathy, which is caused 
by osmotic swelling of brain cells (Giulani and Peri, 2014). Severe hypernatremia also has poor 
outcomes, including seizures and coma (Lewis 2018). 
In normal kidneys, a phenomenon called pressure-natriuresis helps increase sodium 
excretion from the kidneys when there is increased blood pressure or increased salt intake. As a 
person consumes salt, their blood pressure begins to rise due to increased extracellular fluid 
volume, and the kidneys respond by increasing sodium and water excretion according to the 
pressure-natriuresis curve. This helps return blood pressure to normal. A defect in pressure-
natriuresis due to a kidney disease or damage may lead to hypertension (Guyton et al., 1972).  
 In addition to the kidneys, other components of physiology work in concert to alter 
osmolarity and keep it within a normal limit. However, minimal research has been performed to 
determine how these processes may be altered during repeated sodium deprivations, such as when 
“cheating” on the low salt diet.  
2.2.2 Hormones of Body Fluid Regulation 
2.2.2a Vasopressin 
 Vasopressin is mainly secreted by the paraventricular nucleus (PVN) and supraoptic 
nucleus (SON) in the hypothalamus, then carried via axonal transport to the posterior pituitary to 
be released into the blood (Sherlock et al., 1975). When released, it causes water retention in the 
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kidneys, which helps normalize osmolarity. Conversely, when osmolarity is too low, vasopressin 
is decreased so that water can be excreted through the urine. During normal circumstances, 
vasopressin is present in very low levels in circulation (Robertson et al., 1976). Plasma ADH and 
plasma osmolality are closely correlated (Robertson et al., 1976). Osmotic threshold, or the 
osmolarity at which vasopressin is released, varies between species and even between humans. 
Studies in the US, France, and England found a threshold of approximately 280 mosmol/kg H2O 
(Beardwell, 1971; Fressinaud et al., 1974; Robertson et al., 1976), while a study in Japan found a 
threshold of approximately 265 mosml/kg H2O (Shimamoto and Miyahara, 1976). Stimuli for 
vasopressin release include decreased blood volume, such as hemorrhage and dehydration, or 
increased osmolarity in the extracellular fluid (Dunn et al., 1973). The osmotic threshold may be 
altered by these stimuli, such that vasopressin is released at lower or higher thresholds than in a 
normal state (Dunn et al., 1973; Robertson et al., 1976).  
It is known that osmoreceptors found in circumventricular organs, mainly the subfornical 
organ (SFO), organum vasculosum of the lamina terminalis (OVLT), and area postrema (AP) are 
responsible for sensing osmolarity (G&H). The SFO and OVLT are found in the hypothalamus, 
while the AP is found in the hindbrain. When osmoreceptors sense increased osmolarity, a signal 
is sent to the SON and PVN via glutaminergic neurons to release vasopressin (Honda et al., 
1992). Vasopressin then uses V2 receptors to influence the kidneys to retain water in the distal 
tubules and collecting ducts in order to bring osmolarity to normal, as well as the V1 receptors to 
increase blood pressure. During a hemorrhage, vasopressin can be responsible for increasing 
blood pressure as much as 60 mmHg (G&H). Vasopressin also plays a role in increasing water 
intake, further bringing osmolarity back to normal (Szczepańska-Sadowska et al., 1982). 
Vasopressin is also influenced by the sympathetic nervous system, as decreased stretch of 
baroreceptors due to a drop in blood pressure also stimulates release of vasopressin. Normally, 
baroreceptor feedback acts to inhibit vasopressin release (Berl et al., 1974). Other studies have 
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found that stimulation of alpha receptors results in suppression of vasopressin (Liberman et al., 
1970), while signals through the baroreceptors of the carotid sinus are necessary for blood 
pressure-mediated changes in vasopressin release (Berl et al., 1974). Furthermore, vasopressin 
acts centrally to affect the sympathetic nervous system and control blood pressure. This likely 
occurs through the CVOs, particularly the area postrema, which has connections to areas involved 
in body fluid control, such as the nucleus tractus solitarius (NTS). The presence of vasopressin 
also leads to a reflex sympathoinhibition (Hasser 2000). Sympathoinhibition causes a leftward 
shift in the baroreflex curve, meaning that drops in blood pressure cause less sympathetic 
activation than it would at lower levels of vasopressin. Administration of a V1 antagonist reduced 
the reflex sympathoinhibition caused by circulating vasopressin (Imai et al., 1983). This effect is 
probably mediated through the NTS pathway, since blockade of α2 receptors abolishes 
sympathoinhibition.  
The level of salt intake can alter vasopressin release. During periods of low salt intake, 
vasopressin is suppressed due to low osmolarity (G&H). Conversely, with high salt intake comes 
an increase in osmolarity, which will trigger a release of vasopressin into circulation in order to 
retain water in the kidneys and maintain fluid homeostasis (Cowley et al., 1981). However, it is 
unclear how long vasopressin remains elevated, as normotensive subjects may have normal 
plasma vasopressin despite elevated salt intake and plasma sodium concentration (Cowley et al., 
1981). This may indicate that vasopressin fell quickly after salt loading. This study also showed 
that only hypertensive subjects had increased plasma vasopressin when sodium intake increased, 
though this relationship appeared only after age 50. A comparison was not reported between 
normotensive subjects of different ages, so this relationship may also be present in this group of 
subjects. There is also evidence that the baroreceptor inhibition of vasopressin through GABAA 
receptors is decreased by high salt intake, which may explain some cases of high vasopressin in 
hypertensive subjects if they are consuming large amounts of salt (Kim 2011) 
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Conversely, it has been suggested that vasopressin may also influence salt intake. Since 
vasopressin increases water intake, concurrent increases in salt intake would help prevent hypo-
osmolarity. Intracerebroventricular administration of a V1 receptor antagonist decreased salt 
intake in rats which had been deprived of salt using furosemide and DOCA (Flynn et al., 2002). 
Their results are in disagreement with previous studies, which had reported vasopressin itself 
decreased salt intake (Sato et al., 1997); however, intracerebroventricular vasopressin causes 
seizure-like activity, which in Flynn’s study corresponded with decreases in intake of both salt 
and sucrose. Other models also show evidence of vasopressin influence on intake. For example, 
adrenalectomized rats have elevated hypothalamic vasopressin, which may in part be influencing 
the large salt intakes observed in these animals (Franco-Bourland, 1998), though it would be 
expected to decrease intake given the results of Flynn et al. (2002). The differences may be due to 
differences in adrenalectomy and furosemide models, which stimulate salt through different 
mechanisms. Though much is known that vasopressin plays a role in body fluid control, the 
effects of vasopressin on repeated sodium intake has yet to be demonstrated. While studies have 
explored the effects of single deprivations, it is unclear if repeated sodium deprivations may alter 
levels of vasopressin over time. We are not aware of any research that has studied how 
vasopressin might be altered by repeated episodes of sodium deprivation.  
2.2.2b Norepinephrine and Epinephrine 
 Catecholamines are another important hormone in body fluid control. The 
catecholamines norepinephrine and epinephrine play an important role in maintenance of blood 
pressure through the baroreflex arc. When blood pressure drops, signals are sent to the NTS, 
resulting in disinhibition of excitatory signals from the rostral ventrolateral medulla (RVLM). 
The RVLM sends excitatory signals to preganglionic sympathetic neurons in the 
interomediolateral cell column (IML) in the spinal cord. All of these areas in the brain and others, 
including the CVLM, IVLM, and locus ceruleus stain positive for enzymes involved in 
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catecholamine synthesis, as well as are fos positive during hypotension (Dampney et al., 2003). 
The preganglionic neurons release acetylcholine, while the postganglionic neurons are mostly 
adrenergic, secreting norepinephrine. Varicosities on the nerve fibers contain vesicles of 
norepinephrine, which is released to bind to alpha or beta receptors on the effector organ, such as 
the heart or blood vessels. The sympathetic receptors activate second messengers via these 
receptors to either excite or inhibit the cell. Within the cardiovascular system, alpha receptors are 
important for vasoconstriction of vessels, while beta-1 receptors increase heart rate and 
contractility.  
 The sympathetic system is always activated at a certain “tone” so that the tone can be 
increased or decreased as necessary to maintain homeostasis. The tone is due to a basal rate of 
epinephrine and norepinephrine release from the adrenal medulla, and may be responsible for 
some cases of hypertension. The sympathetic nervous system can experience “resetting” after 
long term increases in tone, where a higher sympathetic tone will be defended as a new baseline 
rather than attempting to bring it back down to the previous baseline. This resetting causes a new 
level of baseline epinephrine and norepinephrine to be released, which may ultimately result in 
hypertension. This has been backed up by evidence that hypertensive patients have decreased 
baroreflex sensitivity (Esler et al., 1977), indicating the normally inhibitory input from the 
baroreceptor is not responding to the increased pressures of hypertension. 
 Catecholamines may be influenced by salt intake. Prior research shows that plasma and 
urinary catecholamines increase with decreasing salt amounts in the diet (Luft et al., 1979; 
Romoff et al., 1979). On the other hand, other studies have shown no change in sympathetic 
nerve activity with the high salt diet (McBryde et al., 2009)., but these may not have taken into 
account the variability of individual response to salt Additionally, there are limitations to all 
methods of measuring sympathetic activity. Measuring sympathetic nerve activity can produce 
different results depending on the area measured, while measuring plasma catecholamines does 
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not provide measurement of minute by minute changes. Regardless of the method employed, past 
research suggests that sympathetic activity is altered by salt intake. 
Salt consumption may also influence body fluid mechanics by altering the baroreflex 
response of the sympathetic nervous system. A study in salt-loaded dogs showed an increase in 
the pressor response to carotid occlusion (Brum et al., 1991). That lab saw the opposite effect in 
dogs deprived of salt, where sodium depletion blunted pressor response (Brum et al., 1991). This 
response was diminished by removal of vagal afferent, indicating this may be due to changes in 
baroreceptor sensitivity. Evidence points to a role for the sympathetic nervous system in salt 
sensitive patients as well. One study (Campese et al., 1982) found that patients who were salt 
sensitive did not have lowered norepinephrine when on a high salt (200 mEq) diet. The 
sympathetic nervous system and catecholamines may also play a role in salt sensitivity, as 
transection of the renal sympathetic nerves results in lower blood pressure in rats given 
deoxycorticosterone, which is a model for salt sensitivity (Jacob et al., 2005). A meta-analysis 
found that there was an overall increase in both norepinephrine and epinephrine in patients on a 
low salt diet compared to a high salt diet (Graudal et al., 2012). While these hormones are useful, 
it is difficult to determine the exact level of activation of the sympathetic nervous system, since 
much of the hormone action occurs within the neurons, target cells, and neuronal junctions. 
Regardless of the mechanism, it is clear that changes to sodium intake can cause alterations in the 
sympathetic nervous system which may affect body fluid regulation, including in salt sensitivity. 
But more research is to be done to determine if alterations in catecholamines are different with 
repeated sodium deprivations.. 
2.2.2c Aldosterone 
 The final hormone to be discussed is aldosterone. Release of aldosterone from the adrenal 
glands is stimulated by decreased blood pressure, which leads to an increase in renal sympathetic 
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activity. This activity causes a release of renin, which increases production of angiotensin II and 
aldosterone (G&H). Increased aldosterone promotes reabsorption of sodium and water from 
urine. Aldosterone also has important interconnections to other body fluid control systems, as 
central mineralocorticoid receptors are found in circumventricular organs and the paraventricular 
nucleus. These can bind aldosterone, which then increases vasopressin and central sympathetic 
tone (Gabor and Leenen, 2013). Additionally, some aldosterone is likely made in the brain, as one 
study found that adrenalectomy did not completely eliminate aldosterone presence in the brain 
after seven days (Gomez-Sanchez et al., 2005).  
Several studies suggest that aldosterone increases salt intake. Administration of 
aldosterone or the precursor deoxycorticosterone acetate (DOCA) increases salt intake in sodium 
replete rats (Rice and Richter, 1943; Fluharty & Epstein, 1983; Wolf, 1965). This increase is 
dose-dependent (Wolf, 1965). Blocking aldosterone alone lowers salt intake (Sakai et al., 1986), 
but salt intake is virtually eliminated when both aldosterone and angiotensin II are antagonized 
(Sakai et al., 1986; Sakai et al., 1987), meaning that one alone is not responsible for stimulated 
salt intake. It has been theorized that both hormones work together to increase salt intake during 
periods of deficiency (Krause and Sakai, 2007). Aldosterone is one of the few hormones that has 
been studied during repeated sodium deprivations, but it has not been shown to be altered with 
repeated deprivations (Sakai et al., 1989). However, whether estrogen changes this result has yet 
to be determined.   
2.2.3 Salt Intake & Water Intake in Animal Models 
Regardless of the physiological data showing harmful effects of excess salt, animals—
including both humans and rats—need salt in order to sustain life. Salt is required for growth and 
bone mineralization (Geerling & Loewy, 2008), as well as maintaining normal osmolality of 
plasma for optimal cellular functioning. Fluid volume and body homeostasis is also involved in 
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maintaining blood pressure. Without salt, a person will experience nausea, cramps, fatigue, and 
appetite loss, among other symptoms. However, there are clearly consequences to excessive 
intake. Therefore, research into the behavior of sodium appetite has provided valuable 
information. There have been numerous studies investigating unstimulated (i.e. baseline), 
stimulated, and “need-free” (i.e. post-deprivation) salt intakes. 
Stimulated intake, or the intake in the period immediately after sodium deprivation, is 
also increased by repeated sodium deprivations (Chow et al., 1992; Falk 1966; Na 2007; Sakai 
1986; Sakai 1987; Sakai 1989). When analyzing studies on stimulated salt appetite, it is necessary 
to consider the particular model used. Dietary deprivation is a technically easy method but short 
time periods on the diet do not elicit a salt appetite, which can confuse interpretations of data 
(Stricker 1991; Wolf 1982). Adrenalectomy, which eliminates endogenous aldosterone, is another 
method of stimulating salt intake. This causes the kidneys to excrete excessive salt, and the rats 
drink large amounts of salt to compensate for the loss. Adrenalectomized rats given no salt 
replacement in their diet die (Richter, 1936). If given exogenous aldosterone, however, they stop 
drinking salt (Wolf, 1965). This method is arguably most effective for specifically studying the 
renin-angiotensin-aldosterone system. Some studies use polyethylene glycol (PEG), which is a 
hyperoncotic colloid that draws water into other spaces. It causes a gradual local edema that does 
not have an impact on blood pressure unless combined with another method like sodium deficient 
chow (Stricker, 1981). Other studies use DOCA, which acts as a hormonal stimulus that signals to 
the body that there is a sodium deficiency in the absence of a true shortage. Finally, some studies 
use furosemide, which leads to an increase in the excretion of salt and water by the kidneys. 
Many studies dealing with furosemide deplete the animals for one day out of a week (Leshem et 
al., 2004; Sakai et al., 1986), which, while helpful for determining immediate depletion effects, is 
not similar enough to a long term low salt diet or long term diuretic use. Some studies also 
combine two or more methods, usually dietary sodium restriction and one other, to produce a 
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more robust salt intake. While all of these methods can provide useful information and insight 
into the physiology of body fluid balance, dietary sodium deprivation alone needs to be studied 
further due to its clinical implications for patients on the low salt diet. 
In rats, the salt intake appears to also be influenced by prior episodes of sodium 
deprivation, as some studies have seen the post-deprivation unstimulated intake increase above 
baseline between deprivation periods (Chow et al., 1992; Leshem et al., 2004; Na et al., 2007; 
Sakai et al., 1989). This enhancement could not be explained by excess natriuresis, as urinary 
sodium concentration was normal, nor by hyponatremia on later depletions, since the plasma 
sodium concentration was also normal. This effect was also long-lasting, as the enhancement in 
intake amounts still occurred even when there were four months between depletions (Sakai et al., 
1989). This phenomenon does not appear to be due to learning, as rats given a bolus of 3% saline 
into the stomach during their first dialysis still drink an increased amount of salt on their second 
(Falk, 1965). Research has also found rats more salt than was necessary to replenish their sodium 
levels, which the authors suggested was due to a delay on ingested fluids correcting sodium 
balance, or due to a delay in the signals to stop drinking (Falk, 1966). However, this effect has 
only been studied in furosemide and intraperitoneal dialysis, not a physiological model like 
dietary sodium deprivation. This could have clinical implications in patients on the low salt diet, 
but more research is needed to understand the mechanisms behind the responses to multiple 
depletions, since prior research has not pointed to a clear cause. 
 
2.3 Estrogen & Body Fluid Regulation 
2.3.1 Mechanism of Estrogen Actions 
 Estrogen has long been known to function as a steroid hormone, affecting the genome by 
binding to nuclear receptors and influencing gene transcription (Heldring et al., 2007). Initially, 
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only one estrogen receptor was known, described as an estrogen binding protein by Elwood 
Jensen in the 1960s (as summarized in Barton et al., 2018). This estrogen receptor (ER) was first 
sequenced and clone in the 1980s (Greene et al., 1986; Walter et al., 1985). In 1996, two studies 
simultaneously characterized a novel nuclear estrogen receptor, which became known as estrogen 
receptor beta (ERβ) (Kuiper et al., 1996; Mosselman et al., 1996). Both ERβ and the previously 
known receptor, ERα, work through the classical or ERE pathway. When estrogen binds these 
receptors, they form dimers that bind to an estrogen response element (ERE), which is a section 
of DNA for ER binding. This is found in the promoter region of a target gene and will induce or 
inhibit transcription (Kushner et al., 2000). The ERs may alter transcription by recruiting 
activators or inhibitors. ERs may also function through the AP-1 pathway, where they interact 
with protein complexes in the fos/jun family and change transcription or cell activity. This 
pathway does not require DNA binding, and the ERs do not form a dimer (Paech et al., 1997).  
Additionally, a G-coupled protein receptor, called GPER, was recently discovered 
(Filardo et al., 2007). It was first found in uterine and liver plasma membrane fractions in 1977 
(Pietras and Szego, 1977), but was not cloned until the 1990s (Bonini 1997; Carmeci 1997; 
Owman et al., 1996). This membrane-associated receptor may be responsible for some of the 
rapid nongenomic effects observed in the presence of estrogen, since nuclear receptors act much 
more slowly. Nongenomic actions likely occur through protein-kinase cascades, such as 
adenylate cyclase, MAP kinase or PI3-kinase (Björnström and Sjöberg, 2005). One particular 
study (Filardo et al., 2007) found that GPER was associated with increased cAMP which led to 
downstream effects. The protein kinase pathways may also alter responses to neurotransmitters 
by altering the responsiveness of potassium and calcium channels in neurons (Malyala et al., 
2005). Actions through plasma receptors like GPER may also indirectly lead to genomic effects 
by altering transcription factors such as c-fos (Albanito et al., 2007), which can then alter gene 
transcription as previously described (Björnström and Sjöberg, 2005).  
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Estrogen plays an important role in body fluid regulation, likely through both nuclear and 
plasma membrane receptors. Both during pregnancy and during normal menstrual cycles, body 
fluid balance changes drastically (for review, see Summy-Long and Kadekaro, 2002). Estrogen 
receptors are found throughout areas important to body fluid regulation, including the vessels, 
hypothalamus, and kidneys (Santollo and Daniels 2015; Sladek and Somponpun 2008). GPER is 
found in human blood vessels and plays a role in blood pressure (Haas et al., 2009). While it is 
likely that estrogen causes changes in body fluid regulation. 
2.3.2 Estrogen Effects on Physiology of Body Fluid & Blood Pressure Control 
 As previously mentioned, throughout much of life, women have lower blood pressures 
than men. This may be due, at least in part, to the presence of estrogen. Estrogens have been 
found to increase vasodilators such as NO (Weiner et al., 1994). In fact, research has suggested 
that lack of modulation of the RAAS and NO system in postmenopause can lead to an increase in 
salt sensitivity, as summarized in Pilic et al. (2016). Pressure-natriuresis is also affected by 
estrogen, as females show a leftward shift in the pressure-natriuresis curve. Compared to males, 
they excrete more sodium at the same blood pressure (Hilliard et al., 2011). More research is 
necessary to determine the effects estrogen has on the physiology of body fluid balance, but 
growing research points to alterations in body fluid hormones. 
2.3.3 Estrogen Effects on Hormones of Body Fluid Regulation 
2.3.3a Vasopressin 
 While it appears that vasopressin is altered by estrogen, there is much disagreement 
among studies about estrogen’s effects on vasopressin. In postmenopausal women and in 
ovariectomized rats, estradiol replacement increases vasopressin (Bossmar et al., 1995; Skowsky 
et al., 1979). Additionally, the threshold for sodium-induced vasopressin release appears to be 
reduced by estrogen (Ota et al., 1994), perhaps to defend low plasma sodium and high blood 
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volume for pregnancy and lactation. On the other hand, some research has shown decreases in 
vasopressin with high doses of estrogen and increases with low doses, which would point to the 
dosage of estrogen being at least partially responsible for differences in results between studies 
(Peysner & Forsling, 1990). Other studies have found no change in vasopressin related to the 
estrus cycle, nor when ovariectomized females were given supraphysiological doses of estrogen, 
even though ovariectomy increased plasma vasopressin (Crofton et al., 1985). This study also 
found that males had increased vasopressin compared to females, though it was unclear whether 
this was due to differences in renal clearance of vasopressin, sex steroids, or some other factor. 
However, other research only found estrogen-related differences in vasopressin during 
dehydration (Wang et al., 1996). Sladek et al. (2000) found that osmotically stimulated release of 
vasopressin was blocked by estradiol and decreased mRNA, but this study was done in explants 
and does not give the full picture of what is happening in a whole animal. All of these varying 
results may be due to methodological differences between studies, perhaps in the dosage or 
delivery method of estrogen. It is clear that more research needs to be done in this area. 
Regardless of the direction of change, the literature does point to possible mechanisms 
for how estrogen may alter vasopressin. Some studies have theorized estrogen may alter 
vasopressin release and action through both genomic and nongenomic effects. It is known that 
ERβ is found in the supraoptic nucleus (SON) and paraventricular nucleus (PVN), areas involved 
in vasopressin release (Sladek et al., 2000). Wang et al. found that in vitro treatment of brain 
slices with 17β-estradiol induced exocytosis of vasopressin within 5 minutes, much faster than to 
be expected from genomic effects (1995). Given this information, estrogen may be working 
through nongenomic effects, such as G-coupled receptors, tyrosine phosphorylation, or 
interaction with other receptors like GABAA or glutamate, which would occur more quickly than 
classic estrogen receptors (Sladek et al., 2000). 
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Despite what is known about vasopressin, both with and without estrogen, we are not 
aware of any research investigating how repeated sodium deprivations affects vasopressin, and 
how estrogen may alter any response. This is an area that remains to be explored. 
2.3.3b Norepinephrine and Epinephrine 
 Catecholamines are also altered by estrogen, but studies are conflicted as to how. Studies 
in brain tissue have shown estrogen-induced increases (Serova et al., 2002) and decreases 
(Arbogast and Hyde, 2000) of the mRNA for tyrosine hydroxylase, one enzyme in the 
biosynthetic pathway for catecholamines. A different study found no difference in levels of TH in 
the adrenal medulla (Macova et al,, 2008). Differences in studies may be due to age of animals, 
dosage of estradiol, or other methodological factors. However, tyrosine hydroxylase is also 
involved in dopamine synthesis, and therefore may not be directly indicative of levels of 
catecholamines such as norepinephrine and epinephrine, which play a more direct role in body 
fluid control. Unstimulated levels of norepinephrine are increased by estradiol treatment of 
bovine adrenal medullary cells (Yanagihara et al., 2006), but this may not be representative of 
what occurs in the body, nor what occurs during a challenge such as a low salt diet. It is also 
possible estrogen may modulate norepinephrine or epinephrine’s effects at the organ level. Acute 
injection of estradiol has no effect on sympathetic response to phenylephrine, but chronic 
injection increases baroreflex sensitivity, in that sympathetic nerve activity still increased in 
response to increases in blood pressure despite a lower baseline (He et al., 1998). Some studies 
found the vasoconstrictor effect of norepinephrine increases with estradiol treatment (Colucci et 
al., 1982). While it seems contradictory to other studies which show decreases in components of 
the sympathetic nervous system, increased responsiveness to catecholamines could play a role in 
maintaining blood pressure while catecholamine levels are low. As can be seen, the research 
surrounding estrogen and catecholamines is conflicting. In addition, we are not aware of any 




 Aldosterone is also known to be altered by estrogen. Aldosterone has been found to be 
higher in men than women (Miller et al., 1999). In animals, aldosterone secretion is increased 
after ovariectomy and blocked by estrogen replacement (Roesch et al., 2000). Peripherally, 
estrogen likely acts synergistically through the ERβ and GPER receptors, which are inhibitory 
and stimulatory, respectively (Caroccia et al., 2014). These are both found in the zona 
glomerulosa, and siRNA knockdown of ERβ in adrenal tissue resulted in increases in levels of the 
gene for aldosterone synthase, while silencing the GPER gene decreased it (Caroccia et al., 2014). 
This is corroborated by evidence that aldosterone synthesis is reduced by estrogen (Macova et al., 
2008; Roesch et al., 2000). Additionally, levels of renin and aldosterone fluctuate with the cycle 
(Fommei et al., 2016).  
Estrogen is likely playing a role in regulating aldosterone in the brain as well, as siRNA 
knockdown of ERβ in the RVLM and PVN increases aldosterone-induced hypertension. This 
implies that estrogen may have a protective role against aldosterone-induced hypertension. In 
fact, giving agonists of ERα or ERβ to ovariectomized rats reduces aldosterone-induced 
hypertension (Xue et al., 2013). Additionally, reactive oxygen species production from 
aldosterone is increased in the SFO and PVN by knockdown of both ERα and ERβ (Xue et al., 
2013).  
Minimal research has been done on aldosterone’s response to repeated sodium 
deprivations, and what has been done used furosemide-induced deprivations. Sakai et al. reported 
no differences in levels of aldosterone between males and females, despite sexually dimorphic 
behavioral responses to the deprivations (1989). This research is instructive, but needs to be 
confirmed in dietary sodium deprivations. Additionally the research of Sakai et al. did not 
directly evaluate the role of estrogen, as they only used intact male and female rats. Research 
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needs to be done using both intact and ovariectomized female rats to determine if any differences 
occur.  
2.3.4 Estrogen Effects on Salt Intake 
 There is some evidence for a sex difference in salt intake. Rats are prandial drinkers; 
therefore, it is hard to determine what effect estrogen has on intake when water and food are both 
ad libitum. Because of this there is conflicting reports on effects of estrogen on intake in sodium 
replete animals. Early studies do suggest that spontaneous salt ingestion is affected by estrogen in 
both males and females (Fregly, 1973). Unstimulated salt intake has also been shown to vary with 
the rat’s estrus cycle, with decreased intake during high plasma estrogen, as summarized in 
Antunes-Rodrigues, et al. (2013). Seminal research in the field found that the sexual dimorphism 
in salt intake appears after 60 days of age, which is around when sexual maturity occurs in rats 
(Křeček et al,, 1972). In this study, they found that females ultimately drink a more concentrated 
solution than males at greater volumes per body weight. One study found a decreasing chorda 
tympani nerve response to salt in male, oil-treated females, and then EB-treated female rats 
(Curtis and Contreras, 2006). This correlated with an increasing intake of salt, meaning that 
estrogen may affect  the palatability of salt, and therefore influence intake.  
A critical question is whether salt intake varies when a salt appetite is stimulated in 
estrogen-treated rats. Much of the previous literature has compared intact males and females, 
rather than gonadectomized, which can better discern between the effects of testosterone and 
estrogen. Various studies have reported that intact female rats drink more salt immediately after 
one deprivation than males (Sakai et al., 1989). Some authors suggested that the stimulated intake 
after one deprivation is no different, as females drink larger amounts more quickly before males 
catch up (Chow et al., 1992). However, it is important to note that this study may ultimately 
demonstrate that females drink more than males if the data were expressed as per body weight, 
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but the authors did not record body weights for that particular experiment. Confusion still exists, 
however, as other authors have found that males drink more than females in various models of 
deprivation that stimulate robust sodium appetite (Scheidler et al., 1994; Stricker et al., 1991). A 
number of questions regarding the timing of gonadal hormone treatment remain to be answered. 
Some research has suggested that sex steroids like estrogen and testosterone may have an 
organizational effect in the brain. Females ovariectomized at one day old increase stimulated salt 
intake as adults compared to intact females, while castrated males increase intake to levels similar 
to intact females (Chow et al., 1992). However, the effects later in life has been drawn into 
question, as neither ovariectomy nor orchiectomy at 100 days of age changed salt intake in this 
study (Chow et al., 1992). However, other research found that ovariectomy in adulthood 
increased female stimulated salt intake, and was decreased again by physiological doses of 
estrogen (Stricker et al., 1991). Furthermore, it may be that estrogen leads to increased salt intake 
in females as an adaptation for pregnancy (Curtis, 2015; Kensicki et al., 2002), as this is a state of 
increased blood volume during which fluctuations in osmolarity may occur. Therefore, it is 
possible estrogen may prime for these responses as a reproductive advantage. 
In addition to the question of salt intake during baseline and stimulated periods, an 
arguably more important question is whether salt intake after exposure to sodium deprivation is 
altered by estrogen. Most of the research regarding the consequences of exposure to sodium 
deprivation has been done in males (Falk et al., 1966; Na et al., 2007; Roitman et al., 2002; Sakai 
et al., 1986; Sakai et al., 1987). Additionally, research in this area has been limited to furosemide-
induced deprivation and intraperitoneal dialysis, which, while instructive, does not provide the 
full picture for clinical application such as the low salt diet in humans. However, these studies 
still provide valuable information. In the time periods after deprivation, female rats show 
increased salt intake above that of male rats and above their baseline prior to deprivation (Chow 
et al., 1992; Sakai et al., 1989). In particular, unstimulated intake increased after successive 
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depletions for both males and females, but was 3% higher in females (Sakai et al., 1989). This 
indicates a possibility of a longer lasting change in sodium appetite, perhaps due to estrogen 
presence in the females. The differences in intake were not explained by net urinary sodium loss, 
nor by plasma angiotensin II or aldosterone levels, both of which rose after the first deprivation 
and did not increase further, as seen in other studies using only males (Sakai et al., 1986). Both 
aldosterone and angiotensin II returned to pre-deprivation levels in between deprivation episodes, 
so they are unlikely to be the explanation for the increased intake in either males or females. The 
effects were not affected by lapse of time, as rats depleted a second time four months after their 
first depletion drank comparable amounts to those which were depleted only a week later. Their 
plasma sodium was also no different than rats never depleted, and the urine sodium did not 
change in different depletions. These results indicate the change in intake is not due to a change 
in sodium handling by the kidney. Additionally, consuming high salt was not necessary to elicit a 
salt appetite, as rats who were not given salt to drink after depletion had no difference in their 
intake between depletions compared to rats that did drink salt.  
Nonetheless conclusions about estrogen’s relationship are limited in these studies, since 
estrogen was not controlled by administering it pharmacologically. Research needs to include 
specific experiments addressing what role, if any, estrogen is playing in these behavioral 
alterations in females. The question still remains, does estrogen increase or decrease sodium 
intake? If so, is this changed by multiple dietary deprivations? While it is likely that estrogen 
causes changes in body fluid regulation, more research is needed to determine the exact 
mechanisms behind its effects, which hormones estrogen influences, and how they relate to each 
other. 
This dissertation aims to address this gap in the literature. Given what is known, we 
hypothesized that estrogen alters behavioral and hormonal responses during repeated episodes of 




Aim 1: Behavioral effects of repeated dietary sodium deficiency (rNaD) on female rats with and 
without estrogen. I will analyze salt and fluid intake to test the hypothesis that estrogen status 
changes compensatory behavioral responses to dietary sodium deficiency during repeated 
episodes of sodium deficiency. 
Aim 2: Physiological effects of repeated dietary sodium deficiency (rNaD) on female rats with 
and without estrogen. I will use ELISA to measure plasma levels of vasopressin, catecholamines, 
and aldosterone, as well as using an ion selective electrode to measure plasma sodium, to test the 
hypothesis that estrogen status alters hormone concentrations and plasma sodium levels during 







3.1 General Methods 
3.1.1 Animals, Ovariectomy, Hormone Replacement 
 All procedures were approved by Oklahoma State University Center for Health Sciences 
IACUC. Adult female Sprague-Dawley rats (85 days old) were purchased from Charles River 
Laboratories. Rats were housed two to a cage with ad libitum access to standard food and water 
for one week in a temperature and humidity controlled colony room on a 12:12 dark:light 
schedule (lights on at 07:00). After one week of acclimation, rats were pre-treated with oral 
meloxicam (0.15 mL of 1.5 mg/mL; io), weighed, and anesthetized using inhaled isoflurane. An 
incision was made on the abdomen, the uterus was exposed, and the uterine horns and ovaries 
identified. Each horn was tied with suture approximately 1 cm from the ovary, the arteries were 
cauterized, and the ovary was excised. Incisions were closed with suture in the muscle and staples 
in the skin. Rats were allowed to recover on heated pads, before being placed in individual cages 
and allowed to recover for one week with ad libitum access to standard rat chow (Harlan-#2018; 
0.2% Na) and water. During the recovery week, rats were weighed daily and considered to be 
recovered when they regained pre-operative weight. 
 One week post-ovariectomy, rats were given injections of estradiol benzoate suspended 
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in sesame oil (EB; 0.1 μg/mL, s.c.) or of OIL vehicle (0.1 mL, s.c.). To mimic the pattern of 
estrogen fluctuations during the estrous cycle, injections were given on day one and day two each 
week throughout the experiment. Rats were weighed on injection days and again on day four each 
week of the injection protocol throughout the experiment (see Section 3.4 Verification of 
Estrogen below). 
 
3.2 Single Sodium Deprivation Protocol 
3.2.1 Testing 
At the end of the recovery period, rats received a 50 mL bottle of 0.5 M NaCl overnight 
to adapt to the taste of salt. Twenty-four hours later, the OIL and EB injection protocol was begun 
as described in Section 3.1.1; OIL- and EB-treated rats were assigned to control or dietary sodium 
deficiency conditions. Control OIL- and EB-treated rats (sCon) were maintained on regular chow 
(NaR) throughout. Other OIL- and EB-treated rats were placed on a schedule of alternating weeks 
of NaR or sodium deficient chow (NaD; Harlan; 0.01-0.02% Na), as shown in Figure 1. 
At the end of each diet period, rats were given a two-bottle test in which they received a 
graduated 50 mL bottle of 0.5 M NaCl (salt) and a 50 mL bottle of ddH2O (water). Intakes of salt 
and water were measured after two hours. The 2-bottle test conducted after the first period of 
NaR was considered to be baseline intake. On the last day of NaD, some OIL- and EB-treated rats 
were randomly assigned to receive a final 2-hour, two-bottle test (sNaD+) and were sacrificed 
approximately 10-20 minutes later. Other OIL- and EB-treated rats did not receive a final two-





  The testing sequence is summarized as follows (see also Figure 1): 
1. One week of NaR during recovery after ovariectomy (no injections) 
a. Overnight access to 50 mL bottle of NaCl at end of week (adapt to NaCl) 
2. One week of NaR 
a. OIL and EB injections begin (see section 3.1.1 Animals, Ovariectomy, Hormone 
Replacement) 
b. Two-bottle test at end of week (Baseline intake) 
3. 10 days of NaD 
a. Two-bottle test at end of 10 days (sNaD+) or no 2-bottle test (sNaD-, sCon) 
b. sNaD+/- and sCon rats sacrificed 
 
 
 At the end of the 10-day period of NaD (or comparable period of NaR for control rats), 
rats were rendered unconscious with CO2, then decapitated to collect trunk blood into heparinized 
tubes. Brains were removed and stored at -80°C. Trunk blood was centrifuged and plasma sodium 
concentration (see Section 3.4 Verification of Estrogen); the remainder was stored in Eppendorf 
Figure 1. Timeline for single sodium deprivation protocol. OVX = ovariectomy; NaR = regular chow; NaD = sodium 
deficient chow; # indicate days of OIL or EB injections; * indicate days of 2-hour, two-bottle tests (0.5 M NaCl and 
water). Control groups (sCon) received NaR throughout; some OIL- and EB-treated rats that underwent repeated 
episodes of NaD received a final two-bottle test prior to sacrifice (sNaD+), whereas others did not (sNaD-, sCon). 
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tubes at -80°C. Uteri were also removed and stored in 0.15 M NaCl at 4°C prior to assessing 
uterine weights as described in Section 3.4.2 below. 
 The single deprivation groups are described in Table 1 below.  
Table 1. Summary of the single deprivation experimental groups. Groups differ based on the 
exposure to sodium deficient chow (sNaD, sCon) and presence or absence (+, -) of final two-
bottle test (Sodium Repletion) before being sacrificed. 
 
Group sNaD+ sNaD- sCon 
NaD Exposure 1 episode 1 episode None 
Sodium 
Repletion 
Yes No No 
 
3.2.2 Plasma Hormone Levels 
 Plasma was assayed for circulating levels of aldosterone, vasopressin, epinephrine, and 
norepinephrine using commercially available ELISA kits. Kits were purchased from Enzo 
(aldosterone), MyBioSource.com (vasopressin), Biomatik (epinephrine), and LSBio 
(norepinephrine) and were run according to the manufacturers’ protocols.  
 
3.3 Repeated Sodium Deprivation Protocol 
3.3.1 Testing 
At the end of recovery, a different group of ovariectomized rats received a 50 mL bottle 
of 0.5 M NaCl overnight to adapt to the taste of salt, 24-hours hours later the OIL and EB 
injection protocol was begun, and OIL- and EB-treated rats were assigned to control or NaD 
conditions as described in Section 3.2.1.  
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The testing sequence follow that detailed in Section 3.2.1., but with repeated episodes of 
NaD, as described below (see also Figure 2). Similar to procedures outlined in Section 3.2.1, on 
the day of sacrifice rats were randomly assigned to receive a final two-bottle test (rNaD+), or did 
not receive one (rNaD-, rCon).  
1. One week of NaR post-ovariectomy (no injections) 
a. Overnight access to 50 mL bottle of NaCl at end of week (adapt to NaCl) 
2. One week of NaR 
a. OIL and EB injections begin 
b. Two-bottle test at end of week (Baseline intake) 
3. 10 days of NaD 
a. Two-bottle test at end of 10 days (all groups) 
4. 18 days of NaR 
a. Two-bottle test at end of each week 
5. 10 days of NaD 
a. Two-bottle test at end of 10 days (rNaD+) or no 2-bottle test (rNaD-, rCon) 
b. rNaD+/- and rCon rats sacrificed 
Rats were sacrificed and brains, uteri, and blood were collected and stored as described in 






Figure 2. Timeline for repeated sodium deprivation experiment. OVX = ovariectomy; NaR = regular chow; NaD = 
sodium deficient chow; # indicate days of OIL or EB injections; * indicate days of 2-hour, two-bottle tests (0.5 M NaCl 
and water). Control groups (rCon) received NaR throughout; some OIL- and EB-treated rats that underwent repeated 
episodes of NaD received a final two-bottle test prior to sacrifice (rNaD+), whereas others did not (sNaD-, sCon). 
 
 
The groups are summarized in Table 2.  
Table 2. Summary of the repeated deprivation experimental groups. Groups differ based on 
exposure to sodium deficient chow (rNaD, rCon) and presence or absence (+, -) of final two-
bottle test (Sodium Repletion) before being sacrificed. 
Group rNaD+ rNaD- rCon 
NaD Exposure 2 episodes 2 episodes None 
Sodium 
Repletion 
Yes No No 
 
3.3.2 Plasma Hormone Levels 
Trunk blood was collected for analyses of aldosterone, vasopressin, epinephrine, and 




3.4 Verification of Estrogen Treatment and Sodium-Deficient Diet Effectiveness 
3.4.1 Body Weights 
 Rats were weighed on injection days (day 1 and 2) and two days after the second 
injection (day 4) each week.  
3.4.2 Uterine Weights 
Uteri were removed and stored in 0.15 M saline at 4°C as described in Section 3.1.1. 
Uteri were placed in fresh 0.15 M saline, one horn was isolated, and stripped of fat. A 1 cm 
section was cut and blotted, then weighed in a pre-weighed weigh boat.  
3.4.3 Plasma Protein Concentration 
 After trunk blood was centrifuged as described in Section 3.1.1, a drop of plasma was 
used to analyze plasma protein for each rat with a refractometer (Leica). 
3.4.4 Plasma Sodium Concentration 
 Approximately 100 μl of plasma was collected and frozen at -80°C until analyzed 




Data are presented as means ± SEM. All data were analyzed using ANOVAs as described 
in the sections below;  significance was set as p<0.05. Statistically significant main effects or 
interactions were further analyzed using Fisher’s LSD tests. Rats that did not consume any salt 




3.5.1 Verification of Estrogen Treatment and Sodium-Deficient Diet Effectiveness 
Body weights were analyzed as change in body weight from day 1 to day 4 of each week. 
Since the time courses for the experiments were different, we analyzed body weight changes 
separately for single and repeated deprivation protocols. Single deprivation protocols used a 2-
way repeated measures ANOVA with hormone (OIL or EB) and days as factors, repeated for 
days. Con and NaD animals were analyzed using separate rmANOVAs. Repeated deprivation 
protocols were analyzed using a 3-way repeated measures ANOVA with hormone (OIL or EB), 
condition (control, NaD), and days as factors, repeated for days. 
We compared uterine weights, plasma protein concentrations, and plasma sodium 
concentrations for rats that underwent single or repeated episodes of sodium deprivation using 3-
way ANOVAs with hormone (OIL or EB), condition (control, NaD+, NaD-), and deprivations 
(single or repeated) as factors. Z-scores were calculated for uterine weights only in each group, 
but no outliers were found. 
3.5.2 Salt and Water Intakes  
 All salt and water intakes were normalized to mL of fluid consumed per 100 g of body 
weight for each rat.  
3.5.2a Baseline intakes 
To ensure that there were no differences in intake prior to deprivation, baseline intakes 
were compared. NaD+ and NaD- groups were combined for analyses into a single NaD group. 
Baseline salt and water intakes for sNaD rats were analyzed using a 2-way ANOVA with 




3.5.2b Stimulated and Unstimulated Intakes after Repeated Dietary Sodium Deprivation 
rNaD rats were analyzed separately since the timeline was different. NaD+ and NaD- 
groups were combined for analyses into a single NaD group, and salt and water intakes during 
Baseline, NaD-1, Recovery-1, and Recovery-2 periods were analyzed using a 3-way repeated 
measures ANOVA with hormone (OIL or EB), diet (control or NaD), and day as the factors, 
repeated for day.  
3.5.2c Test day intakes 
 These analyses compared intakes by sNaD+ and rNaD+ on the final day of NaD prior to 
sacrifice (because the NaD- and Con groups were sacrificed without a two-bottle test on the final 
day, these rats were not included in these analyses). Intakes by sNaD+ and rNaD+ rats on the test 
days were compared in a 3-way ANOVA with hormone (OIL or EB), diet (control or NaD), and 
number of deprivations (repeated or single) as the factors. Fluid concentrations consumed were 
analyzed by 3-way ANOVA with hormone (OIL or EB), diet (control or NaD), and number of 
deprivations (repeated or single) as the factors. 





and were analyzed by 2-way ANOVA with hormone (OIL or EB) and number of deprivations 
(repeated or single) as the factors. Specific planned comparisons were made with Fisher’s LSD 
using Bonferroni corrections. 
3.5.3 Plasma Hormone Levels 
 Plasma hormone levels were normalized to protein concentration found via Bradford 
assay. Z-scores were calculated for each plasma hormone level and values more than two 
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standard deviations from the mean were eliminated from that particular analysis. We compared 
plasma aldosterone, norepinephrine, epinephrine, and vasopressin levels in rats that underwent 
single or repeated episodes of sodium deprivation using a 3-way ANOVA with hormone (OIL or 
EB), diet (control, NaD+, NaD-), and number of deprivations (single or repeated) as factors. 
Values from individual hormone assays greater than two standard deviations from the mean were 







4.1 Verification of Estrogen Treatment and Sodium-Deficient Diet Effectiveness 
4.1.1 Body Weights 
Rats were comparable in weight during the post-OVX recovery period (OIL=285.6 g +/- 3.1 g; 
EB=281.5 g +/- 3.5 g). For the purposes of illustration, raw body weights are shown in Figures 3 





Figure 3. Raw body weights, single deprivation. Raw body weights (g) of OIL- (light blue circles) and EB-treated (dark 
blue circles) rats during the single dietary sodium deprivation protocol.  
 
Figure 4. Raw body weights, repeated deprivation. Raw body weights (g) of OIL- (light blue circles) and EB-treated 
(dark blue circles) rats during the repeated dietary sodium deprivation protocol. 
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Tables 3 and 4 show the change in body weight between day 1 and day 4 each week for rats in the 
single and repeated deprivation protocols. 
Table 3. Change in body weight, single dietary sodium deprivation. Change in body weight(g) 
between day 1 and day 4 during each week of the single dietary sodium deprivation protocol. 
NaR = regular diet; NaD = sodium deficient diet; Con = Control; OIL = Oil-treated; EB = 
Estrogen-treated. * = significantly less weight gain than OIL-treated animals overall; 1 = 
significantly more weight loss than all other weeks. 
 Week 1 Week 2 Week 3 
Con 
 NaR NaR  
OIL 15.3 ± 2.4 17.3 ± 1.7 nd 
EB* -8.5 ± 1.8 -7.2 ± 2.9 nd 
NaD 
 NaR NaD-11 NaD-1 
OIL 15.8 ± 1.5 3.5 ± 2.4 8.2 ± 1.4 
EB* -7.2 ±1.4 -10.2 ± 2.9 -6.2 ± 1.9 










Table 4. Change in body weight, repeated dietary sodium deprivation. Change in body weight 
(g) between day 1 and day 4 during each week of the repeated dietary sodium deprivation 
protocol. NaR = regular diet; NaD = sodium deficient diet; Con = Control; OIL = Oil-treated; EB 
= Estrogen-treated. * = significantly less weight gain than OIL-treated animals overall; ** = 
significantly greater weight gain than other groups; • = significantly greater weight loss than all 
other groups; 1 = significantly greater weight gain than all other time periods; 2 = significantly 
greater weight loss than Weeks 1, 3, 4; 3 = significantly greater weight loss than all other weeks. 
 Week 11 Week 22 Week 3 Week 4 Week 5 Week 63 Week 7  
Con 
 NaR NaR NaR NaR NaR NaR NaR 
OIL 14.5 ± 0.9 ** 17.5 ± 1.1 10.2 ± 1.7 5.3 ± 1.1 4.2 ± 1.2 2.7 ± 0.9 0.8 ± 2.3 
EB* -3.7 ± 2.7 2.5 ± 1.7 -1.7 ± 1.9 -2.0 ± 1.1 -8.0 ± 1.2 -6.5 ± 0.9 • -4.7 ± 2.3 
NaD 
 NaR-1 NaD-1 NaD-1 NaR-2 NaR-2 NaD-2 NaD-2 
OIL 14.1 ± 1.1 ** -1.7 ± 2.2 10.8 ± 1.8 4.9 ± 1.3 3.3 ± 1.2 -1.2 ± 1.9  2.4 ± 1.2 
EB* -3.3 ± 1.6 -12.8 ± 1.6 -6.5 ± 1.3 -4.8 ± 1.6 -5.6 ± 1.2 -16.8 ± 3.0 • -5.8 ± 1.3 
  
In single NaD protocol, a two-way rmANOVA of the NaD diet condition rats found a 
main effect of hormone [F(1,46)=118.42, p<0.001] on the change in body weight. There was also 
a main effect of time [F(2,46)=6.93, p<0.01]. The time by hormone interaction approached but 
did not reach significance [F(2,46)=3.16, p=0.052]. Pairwise comparisons of time using LSD 
showed that the NaD rats lost more weight on week 2 (NaD-1) than all other times. 
 In single NaD protocol, a two-way rmANOVA of the Con diet condition rats found a 
main effect of hormone [F(1,10)=79.04, p<0.001] on the change in body weight. 
In repeated NaD protocol, a three-way rmANOVA found a main effect of hormone 
[F(1,216)=178.91, p<0.001] and of diet [F(1,216)=18.71, p<0.001] on the change in body weight. 
There was also a main effect of time [F(6,216)=14.48, p<0.001]. There was a significant time by 
hormone interaction [F(6,216)=3.85, p<0.01], and a time by diet interaction [F(6,216)=11.80, 
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p<0.001]. Pairwise comparisons of time using LSD showed that, overall rats gained significantly 
more weight gain on week 1 (NaR-1) than all other times, and lost significantly more weight loss 
on week 6 (NaD-2) than all other times.  
In addition, there was a time by hormone interaction [F(6,216)=3.85, p<0.01]. Pairwise 
comparisons of this interaction found that, independent of diet condition, OIL-treated rats had 
greater weight gain during week 1 (NaR-1) than all other treatments and time points, whereas EB-
treated rats had greater weight loss in week 6 (NaD-2) than all other treatments and time points, 
regardless of diet condition. 
Finally, there was also a time by diet interaction [F(6,216)=11.80, p<0.001]. Pairwise 
comparisons of this interaction showed that, overall, the change in body weight was altered 
during NaD periods (greater weight loss in EB-treated rats, attenuated weight gain in OIL-treated 
rats), demonstrating efficacy of the sodium deficient chow. 
4.1.2 Uterine Weights 
Uterine weights are shown in Figure 5 below. Three-way ANOVA revealed a main effect 
of hormone [F(1,64)=347.85, p<0.001] and of the number of deprivations [F(1,64)=7.15, p<0.01]. 
Three-way ANOVA also showed an interaction between the number of deprivations and the diet 
condition [F(2,64)=4.44, p<0.05]. Pairwise comparisons of this interaction showed that 




Figure 5. Uterine weights of OIL- and EB-treated rats. Uterine weights (mg) in OIL- (light blue bars) and EB-treated 
(dark blue bars) rats. Some rats were given one dietary sodium deprivation with (sNaD+ ) or without (sNaD-) sodium 
repletion before sacrifice. Other rats had repeated dietary sodium deprivations with (rNaD+) or without (rNaD-) 
sodium repletion. Control rats (sCon and rCon) were not sodium deprived.  # = significantly greater than all other rats 
except sNaD-; & = significantly less than single deprivation animals; * = significantly greater uterine weight in EB-
treated rats, overall. 











4.1.3 Plasma Protein Concentration 
Plasma protein concentration is shown in Figure 6. Three-way ANOVA showed a main 
effect of deprivation [F(1,65)=16.39, p<0.0001], condition [F(2,65)=16.23, p<0.0001] and 
hormone [F(1,65)=210.76, p<0.0001], with no interactions among the variables. Pairwise 
comparisons of the main effect of diet condition revealed that NaD+ rats had significantly lower 
plasma protein concentrations than all other rats, independent of hormone or number of 
deprivations.  
 
Figure 6. Plasma protein concentration in OIL- and EB-treated rats. Plasma protein concentration (g/dL) in OIL- (light 
blue bars) and EB-treated (dark blue bars) rats. Some rats were given one dietary sodium deprivation with (sNaD+ ) or 
without (sNaD-) sodium repletion before sacrifice. Other rats had repeated dietary sodium deprivations with (rNaD+) 
or without (rNaD-) sodium repletion. Control rats (sCon and rCon) were not sodium deprived.  * = significantly greater 
than OIL-treated rats; & = significantly greater than rats in single deprivation protocol; # = significantly less than NaD- 






4.1.4 Plasma Sodium Concentration 
Three-way ANOVA of plasma sodium concentrations (Figure 7) revealed a main effect 
of hormone [F(1,61)=5.97, p<0.05] and of diet condition [F(2,61)=5.71, p<0.05], with 
significantly greater sodium concentration in NaD rats that were allowed to replete their sodium. 
There was also an interaction between the number of deprivations and diet condition 
[F(2,61)=3.49, p<0.05]. Pairwise comparisons of this interaction showed that the rNaD+ group 
had a significantly greater plasma sodium than all other groups, independent of hormone. 
 
Figure 7. Plasma sodium concentration in OIL- and EB-treated rats. Plasma sodium concentration (mmol/L) in OIL- 
(light blue bars) and EB-treated (dark blue bars) rats. Some rats were given one dietary sodium deprivation with 
(sNaD+) or without (sNaD-) sodium repletion before sacrifice. Other rats had repeated dietary sodium deprivations 
with (rNaD+) or without (rNaD-) sodium repletion. Control rats (sCon and rCon) were not sodium deprived. * = 
significantly greater than OIL-treated rats; # = NaD+ significantly greater than all other diet conditions; 1 = 





4.2 Salt and Water Intakes  
4.2.1 Baseline Intakes 
Two-way ANOVA comparing the baseline intakes of salt and water by rats in the single 
deprivation protocol showed no main effects or interactions of hormone or diet condition for salt 
or water intake at baseline (Figures 8 and 9). 
 
Figure 8. Baseline salt intakes by OIL- and EB-treated rats in the single dietary sodium deprivation protocol. Baseline 
salt intakes (mL) by OIL- (light blue bars) and EB-treated (dark blue bars) rats. NaD = rats that underwent dietary 




Figure 9. Baseline water intakes by OIL- and EB-treated rats in the single dietary sodium deprivation protocol. 
Baseline water intakes (mL) by OIL- (light blue bars) and EB-treated (dark blue bars) rats. NaD = rats that underwent 
dietary sodium deprivation; Con = control rats that were not sodium deprived. 
 
4.2.2 Stimulated and Unstimulated Intakes after Repeated Dietary Sodium Deprivation 
A 3-way repeated measures ANOVA of salt intake by rats in the repeated deprivation protocol 
(Figure 10) revealed a main effect of diet [F(1,108)=5.28, p<0.05] and of time [F(3,108)=13.52, 
p<0.0005]. There also was a time by diet interaction [F(3,108)=12.47, p<0.0005] and pairwise 
comparisons of the interaction showed that, independent of hormone, rats drank significantly 
more salt on the NaD diet during the NaD-1 period. In addition, there was a time by hormone 
interaction [F(3,108)=4.76, p<0.005]. Pairwise comparisons of this interaction showed that OIL-
treated rats drank significantly greater amounts of salt water at the NaD-1 diet, regardless of the 
diet condition, and EB-treated rats drank less at baseline than they did at NaD-1, Recovery-1, or 
Recovery-2, independent of the diet condition. Specific planned comparisons using a Bonferroni 
correction of EB-treated rats on the NaD diet condition found that these rats drank more salt 
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during Recovery-1 than at baseline (p<0.05). Surprisingly, there was no difference in Recovery-2 
intake (p=0.07), possibly due to variability in individual intakes. EB-treated rats during baseline 
also drank less than OIL-treated rats at baseline or NaD-1.  
 
Figure 10. Salt intakes by OIL- and EB-treated rats during the repeated dietary sodium deprivation protocol. Salt 
intakes (mL) by OIL- and EB- treated rats during the repeated dietary sodium deprivation protocol at baseline (first 
bar), first dietary sodium deprivation (second bar), first week of recovery (third bar), and second week of recovery 
(fourth bar). Con = control rats (never sodium deprived); NaD = rats that underwent two dietary sodium deprivations. 
Baseline = intake prior to NaD; NaD-1 = intake during first dietary sodium deprivation; Recovery 1, 2 = intake during 
NaR after the first dietary sodium deprivation. # = significantly greater intake than all other time points; & = 
significantly greater intake than Con rats; 1 = significantly greater intake than Con rats after NaD-1 diet period; 2 = 
significantly greater intake than EB-treated rats at baseline. 
 
A three-way repeated measures ANOVA of water intake by rats in the repeated deprivation 
protocol (Figure 11) revealed a main effect of time [F(3,108)=4.79, p<0.005] and a time by diet 
interaction [F(3,108)=4.51, p<0.05]. Pairwise comparisons of the interaction revealed that 





Figure 11. Water intakes by OIL- and EB-treated rats during the repeated dietary sodium deprivation protocol. 
Water intakes (mL) by OIL- and EB- treated rats during the repeated dietary sodium deprivation protocol at baseline 
(first bar), first dietary sodium deprivation (second bar), first week of recovery (third bar), and second week of recovery 
(fourth bar). Con = control rats (never sodium deprived); NaD = rats that underwent two dietary sodium deprivations. 
Baseline = intake prior to NaD; NaD-1 = intake during first dietary sodium deprivation; Recovery 1, 2 = intake during 
NaR after the first dietary sodium deprivation.. # = significantly greater intake than all other time points; 1 = 












4.2.3 Test Day Intakes 
Two-way ANOVA of test day salt intakes by rats in single and repeated NaD protocol 
(Figure 12) revealed no main effects or interaction between hormone or number of deprivations.  
 
 
Figure 12. Test day salt intakes by OIL- and EB-treated rats in the single and repeated dietary sodium deprivation 
protocols. Test day salt intakes (mL) by OIL- (light blue bars) and EB-treated (dark blue bars) rats that received single 









Two-way ANOVA for the test day water intakes (Figure 13) showed no significant main 
effect or interaction.  
 
Figure 13. Test day water intakes by OIL- and EB-treated rats in the single and repeated dietary sodium deprivation 
protocols. Test day water intakes by OIL- (light blue bars) and EB-treated (dark blue bars) rats that received single or 
repeated dietary sodium deprivations. 
 
Two-way ANOVA of the concentration of fluid consumed on test day (Figure 14) 
revealed a significant main effect of hormone [F(1,24)=6.71, p<0.05], with EB-treated rats 
drinking a significantly less concentrated fluid, independent of the number of deprivations. There 





Figure 14. Concentration of fluid consumed on test day by OIL- and EB-treated rats in the single and repeated 
dietary sodium deprivation protocols. Concentration (mOsm) of fluid consumed on test day by OIL- (light blue bars) 
and EB-treated (dark blue bars) rats that received single or repeated dietary sodium deprivations. * = significantly less 

















4.3 Plasma Hormone Levels 
Plasma norepinephrine concentration are shown in Figure 15. Three-way ANOVA 
revealed that there was a main effect of diet [F(2,65)=5.31, p<0.05], and pairwise comparisons 
showed that, independent of hormone, rCon rats had significantly lower plasma norepinephrine. 
There was also a main effect of hormone [F(1,65)=6.81, p<0.05]. EB-treated rats had 
significantly lower plasma norepinephrine, regardless of diet. Although it appears that 
norepinephrine levels in OIL- and EB-treated rats differed depending on the number of dietary 
sodium deprivations, this interaction failed to attain statistical significance.  
 
 
Figure 15. Plasma norepinephrine concentrations for OIL- and EB-treated rats. Plasma norepinephrine concentrations 
(pg NE/pg protein) for OIL- (light blue bars) and EB-treated (dark blue bars) rats. Some rats were given one dietary 
sodium deprivation with (sNaD+ ) or without (sNaD-) sodium repletion before sacrifice. Other rats had repeated dietary 
sodium deprivations with (rNaD+) or without (rNaD-) sodium repletion. Control rats (sCon and rCon) were not sodium 




Plasma epinephrine concentration is shown in Figure 16. Three-way ANOVA showed no 
significant main effects or interactions.  
 
Figure 16. Plasma epinephrine concentrations for OIL- and EB-treated rats. Plasma epinephrine concentrations (pg 
Epi/pg protein) for OIL- (light blue bars) and EB-treated (dark blue bars) rats. Some rats were given one dietary sodium 
deprivation with (sNaD+ ) or without (sNaD-) sodium repletion before sacrifice. Other rats had repeated dietary 










Plasma vasopressin concentration is shown in Figure 17. Three-way ANOVA showed a 
significant main effect of deprivations [F(1,59)=4.41, p<0.05], with rats in the repeated dietary 
sodium deprivations protocol having significantly greater vasopressin levels overall. There was 
also a main effect of diet [F(2,59)=12.92, p<0.001], with rats on the control (Con) diet having 
significantly greater vasopressin levels. In addition, the main effect of hormone [F(1,59)=5.48, 
p<0.05] showed significantly greater vasopressin levels for OIL-treated animals. Finally, there 
was an interaction between diet and hormone [F(2,59)=3.42, p<0.05]. Pairwise comparisons of 
the interaction showed that, independent of the number of deprivations, OIL-treated control rats 
had significantly greater vasopressin levels than all other conditions, including EB-treated 
controls. 
 
Figure 17. Plasma vasopressin concentrations for OIL- and EB-treated rats. Plasma vasopressin concentrations (pg 
VP/pg protein) for OIL- (light blue bars) and EB-treated (dark blue bars) rats. Some rats were given one dietary sodium 
deprivation with (sNaD+ ) or without (sNaD-) sodium repletion before sacrifice. Other rats had repeated dietary 
sodium deprivations with (rNaD+) or without (rNaD-) sodium repletion. Control rats (sCon and rCon) were not sodium 
deprived.  * = significantly less than OIL-treated animals; * = significantly less than OIL-treated animals; & = 
significantly greater than single deprivation animals; # = significantly greater than all other groups. 
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Plasma aldosterone concentrations are shown in Figure 18. Three-way ANOVA showed a 
significant main effect of hormone [F(1,54)=7.10, p<0.05], with EB-treated rats having 
significantly lower plasma aldosterone overall. There were no other main effects or interactions. 
 
Figure 18. Plasma aldosterone concentrations for OIL- and EB-treated rats. Plasma aldosterone concentrations (pg 
aldo/pg protein) for OIL- (light blue bars) and EB-treated (dark blue bars) rats. Some rats were given one dietary 
sodium deprivation with (sNaD+ ) or without (sNaD-) sodium repletion before sacrifice. Other rats had repeated 
dietary sodium deprivations with (rNaD+) or without (rNaD-) sodium repletion. Control rats (sCon and rCon) were not 








 Previous research has seen alterations in salt intake with repeated sodium deficiencies, 
but these mainly used a combined furosemide and low salt diet treatment. We aimed to determine 
the behavioral and physiological effects of repeated sodium deprivations in rats treated with 
estrogen and test the hypothesis that estrogen alters behavioral and hormonal responses during 
repeated episodes of dietary sodium deficiency. We tested this by observing the changes in salt 
and water intake after repeated sodium deprivations, then measured the plasma concentrations of 
norepinephrine, epinephrine, vasopressin, and aldosterone using ELISA.  
 
5.1 Aim 1: Behavioral Changes 
5.1.1 Unstimulated Intakes 
 At baseline, there was no difference in salt or water intake between OIL- and EB-treated 
rats (Figs. 9-11). Unsurprisingly, after sodium deficiency, NaD rats drank more salt to replenish 
that which was lost during deprivation. Water tended to mirror salt intake. Similar to the findings 
by Stricker et al. (1991), we saw that EB treatment resulted in a lower salt intake compared to the 
OIL-treated rats in the two-bottle test immediately following deprivation (NaD-1 intakes, Figure 
11). In the Recovery period, where rats had access to regular chow, OIL- treated rats returned to 
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levels of salt intake similar to baseline. On the other hand, EB-treated rats had Recovery-1 intake 
that was significantly greater than baseline salt intake.  
The increase in Recovery-1 salt intakes in EB-treated rats suggest that there are long-term 
changes where, despite the rats returning to a sodium replete status with access to regular chow, 
they continue to spontaneously consume salt without need, similar to the results seen by others 
such as Sakai et al. (1989). Our data adds to past research by extending this phenomenon to 
ovariectomized rats and further confirming a role for estrogen in this increase in post-deprivation 
unstimulated salt intake. This suggests estrogen is contributing to long term behavioral changes 
after repeated dietary sodium deficiency. Our study also extends the phenomenon to dietary 
sodium deprivation, as previous research had used furosemide to induce sodium deficiency.  
5.1.2 Stimulated Intakes 
 Comparison of test day intakes immediately after NaD-1 or NaD-2 showed no significant 
difference in the salt or water intakes regardless of hormone treatment or number of deprivations, 
in contrast to previous research that showed increases in stimulated salt intake by intact females 
on subsequent sodium deprivations (Chow et al., 1992; Leshem et al., 2004; Sakai et al., 1987; 
Sakai et al., 1989). The observed differences between our study and previous research could be 
due to differences in sodium deficiency models (furosemide vs. dietary) or due to differences 
between endogenous or exogenous estrogen. Many previous studies also did not report the stage 
of estrus cycle during testing, which could obscure results. We chose to ovariectomize the rats 
and deliver estrogen on a four-day cycle to mimic the rat’s natural estrus cycle, control the 
amount of estrogen received, and control the cycle stage at which we tested. Our dosage is meant 
to induce plasma concentrations similar to physiological levels. Regardless, we cannot rule out 
that stimulated salt and water intake vary with the estrus cycle and may be responsible for the 
differences between studies. It is also possible that further episodes of deficiency would increase 
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salt intake over time, as EB-treated rats appeared to drink more salt on the second deprivation, but 
the amount did not reach significance. Further research is needed to determine if repeated dietary 
sodium deprivations would increase stimulated salt intake after more than two deprivations and 
how the response may vary with different estrogen levels. 
 The lack of a difference in water intake was also somewhat surprising, as some previous 
research supports differences in water intake due to estrogen. Other studies had no differences in 
water intake between males and females (Sakai et al., 1989) and no effect of testosterone 
treatment (Chow et al., 1992), but we are not aware of previous studies that specifically studied 
estrogen’s effects on water intake during repeated deprivations. While our data trend toward EB-
treated rats drinking higher amounts of water, it failed to achieve significance.  
Despite the non-significant results for salt and water intakes, when the concentration of 
ingested fluid was calculated, we found that EB-treated rats drank a less concentrated fluid during 
both deprivations. Previous studies have demonstrated an overcorrection of salt ingestion post-
deficiency (Stricker et al., 1991), and our data suggest that perhaps the EB-treated rats are better 
at making adjustments to their water intake and minimizing this overcorrection. Post-ingestion 
signals from the stomach may be responsible for ceasing salt ingestion and switching to water, 
resulting in a less concentrated fluid overall. While we did not record which solution rats drank at 
particular times, other studies have seen that after experiencing sodium deficiency, rats drink 
large amounts of salt initially before alternating salt and water, which could be a means of 
adjusting the concentration of consumed fluid (Stricker et al., 1991). It is also possible that 
estrogen treatment alters taste perception, as it has previously been seen that chorda tympani 
responses to saline are altered by estrogen treatment (Curtis and Contreras, 2006). The chorda 
tympani has connections to gustatory centers in the brain, such as the NTS, which may be further 
altered by both EB and by repeated deprivations. While we did not see statistically significant 
differences in the concentrations of ingested fluid between sNaD and rNaD rats, the EB-treated 
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rats do appear to begin drinking a more concentrated fluid on the second depletion which 
approaches that consumed by the OIL-treated rats. It is possible that further depletions, such as 
the four-depletion protocol implemented by other labs (Sakai et al., 1989) would lead to further 
changes that are not evident after only two depletions, and that after a certain number of 
depletions, this effect of estrogen would diminish. Future studies should explore the effects of 
more depletions using dietary deprivation as in our protocol. 
 It is clear that the dietary sodium deprivation was sufficient to cause behavioral changes. 
EB-treated rats drink a less concentrated fluid immediately after deprivation, but drink more salt 
in the weeks following deprivation. This research must be expanded to determine if these 
behavioral phenomena continue with more episodes of deficiency. 
 
5.2 Aim 2: Physiological Changes Part 1: Body Weight, Uterine Weight, Plasma Protein, 
and Plasma Sodium 
5.2.1 Body Weight 
 EB-treated rats tended to experience decreases in body weight as we expected (Tables 1, 
2). This suggests that our EB treatment protocol was effective. At the same time, both OIL- and 
EB-treated rats exhibited attenuated weight gain (OIL) or augmented weight loss (EB) during the 
weeks of NaD. This effect may indicate loss of extracellular fluid volume in urine as a result of 
the diet. Previous studies showing greater sodium loss in the urine in the initial days on a sodium 
deficient diet support this interpretation (Stricker et al., 1991). Additionally, we saw greater 
weight loss in EB-treated rats on week 6, regardless of the diet condition (NaD or Con). This 
appears to mainly be due to large weight loss in the EB-treated NaD rats, but the reasons for this 
are unclear. It is unlikely to be due to a greater natriuresis in the second deprivation, as this was 
not seen in other studies in furosemide (Sakai et al., 1989). It may be due to prolonged exposure 
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to estrogen, but further studies would be necessary to determine the mechanism behind the 
observed weight loss. 
5.2.2 Uterine Weights 
  Uterine weights were measured as another means to assess EB treatment effectiveness. 
As expected, we saw greater uterine weight in rats that received EB treatment, which has been 
seen in other research (Peysner and Forsling, 1990). Additionally, rats in the repeated deprivation 
protocol had significantly decreased uterine weight regardless of hormone treatment. This is 
possibly due to age, as these rats were four weeks older than single deprivation rats at sacrifice. 
Our sCon group also had significantly greater uterine weight than all other groups, which we 
suspect is due to human error, as some uteri in that group were measured as much larger than all 
others.  
5.2.3 Plasma Protein Concentration 
 Plasma proteins were increased in EB-treated rats as we expected. Previous studies have 
seen increases in plasma proteins with steroid treatments (Roesch et al., 2000), likely due to 
increases in carrier proteins for hormones such as estrogen (Raynaud et al., 1971). Additionally, 
we saw significantly decreased plasma protein in the sNaD+ and rNaD+ groups. Since these 
groups were allowed to consume salt and water within two hours prior to sacrifice, this is likely 
due to a small dilutional effect from consuming fluid. Finally, our repeated deprivation animals 
had significantly elevated plasma protein. Since rCon rats were also increased, it may not be due 
to an effect of the repeated episodes of NaD diet, but instead age. However, if true, it is unclear 





5.2.4 Plasma Sodium Concentration 
 Plasma sodium concentration has previously been shown to be unaltered in both dietary 
sodium deficiency (Stricker et al., 1991) and furosemide deprivation (Sakai et al., 1987). We 
observed an increase in plasma sodium in EB-treated rats, which is supported by previous 
research (Roesch et al., 2000). It has been suggested that sexually mature female rats may more 
closely guard a higher plasma sodium concentration as an adaptation for pregnancy (for review, 
see Weissgerber and Wolfe, 2011). Therefore, it is to be expected that the EB-treated rats have a 
slightly higher plasma sodium despite the low salt diet, and again suggests that our estrogen 
treatment is mimicking physiological estrogen levels. Additionally, increases in the plasma 
sodium concentration in sNaD+ and rNaD+ groups could indicate that these rats did not have 
time to return to baseline after consuming salt during the two-bottle test. Nonetheless, it is clear 
that any behavioral differences between single and repeated deprivations are not due to alterations 
in renal clearance of sodium, since there were no differences in plasma sodium between single 
and repeated deprivations. 
 
5.3 Aim 2: Physiological Changes Part 2: Body Fluid Hormones 
5.3.1 Vasopressin Concentration 
 We found a decrease in plasma vasopressin concentration with EB treatment, which 
supports previous data that found decreased vasopressin mRNA in the brain in the presence of 
estrogen (Sladek et al., 2000) and expands the findings to live animals. Previous data on the 
effects of estrogen on vasopressin secretion have been conflicting, with no change (Crofton et al., 
1985), increases (Skowsky et al., 1979), and decreases (Sladek et al., 2000) all reported. 
However, these differences may be due to methodological differences, such as the delivery 
method or dosage of estrogen.  
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Estrogen receptor beta (ERβ) is expressed in the SON and PVN, areas responsible for 
release of vasopressin. It is believed that ERβ plays an inhibitory role on vasopressin release 
(Sladek and Somponpun, 2008). Therefore, stimulation of this receptor by estrogen circulating in 
the body would result in a decrease in estrogen release, which supports our findings. 
 The increase in vasopressin in repeated deprivation groups is interesting, but it is unclear 
whether this was a factor of the repeated sodium deprivations or age, since it appears that 
vasopressin trended toward increasing in the rCon group compared to sCon. The increase in this 
group may account for the main effect of repeated deprivations. As expected, the sCon and rCon 
groups had higher plasma vasopressin. These results indicate retention of water to maintain 
plasma osmolality while on standard laboratory chow, while the low salt chow suppresses 
vasopressin. Despite this suppression, we were still able to detect vasopressin levels with our 
assay, demonstrating its sensitivity. However, in order to determine whether age or number of 
deprivations are a factor in vasopressin, further studies with more deprivations need to be done. 
We did not see a difference in NaD+ and NaD- groups, despite the NaD+ rats consuming salt 
prior to sacrifice. It is possible that the time course between sodium repletion and sacrifice was 
not long enough for an increase in vasopressin to occur.  
 Our results highlight that vasopressin is affected by estrogen. In the case of subcutaneous 
administration of physiological levels of estrogen, our data support an inhibitory effect of 
estrogen on vasopressin. Further study is needed to evaluate the effect of repeated sodium 
deprivations on plasma vasopressin concentration. Measuring the alterations in ERβ in the SON 
and PVN after repeated deprivations may provide more insight as to whether the differences we 





5.3.2 Norepinephrine and Epinephrine Concentration 
 The consistent decrease in norepinephrine concentration in EB-treated rats suggests that 
these rats were not experiencing as much compensatory increase in the sympathetic nervous 
system in response to dietary sodium deprivation as OIL-treated rats. Over time, the difference 
between OIL- and EB-treated rats appears to increase, though neither group was statistically 
different from the levels observed after a single deprivation. It is possible that an effect of age or 
of repeated estrogen treatments over time may play a role in this growing difference, but longer 
term studies are needed to confirm this. More deprivations may lead to a greater rebound increase 
in norepinephrine in OIL-treated rats over time.  
 As expected, we saw increases in plasma norepinephrine concentration in rats in the 
NaD+ and NaD- groups compared to Con rats. This supports previous studies showing increases 
in catecholamines while on a low salt diet across a broad range of sodium concentrations (Luft et 
al.,  1979; Romoff et al., 1979). However, it was somewhat surprising that norepinephrine was 
not altered by repeated deprivations. This suggests that norepinephrine and, therefore, the 
sympathetic nervous system, are not responsible for the alterations in salt and water intake 
observed in our study and previous studies (Chow et al., 1992; Sakai et al., 1987; Sakai et al., 
1989;). Additionally, we did not see an effect of pre-sacrifice sodium repletion on the 
concentration of norepinephrine, as there was no difference between NaD+ and NaD- groups. The 
time between repletion and sacrifice may have been too short to show a measurable difference.  
 The lack of significant differences in hormone treatment or diet condition for epinephrine 
concentration requires further research. We expected that it would also be altered by dietary 
sodium deprivation, but it is possible that this is not a strong enough stimulus for epinephrine 
release. However, other research has found alterations in epinephrine on the low salt diet 
(Graudal et al., 2012). The reasons for this discrepancy are unclear. Future studies need to explore 
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the differential mechanisms behind norepinephrine and epinephrine release in the context of 
dietary sodium deprivation.  
5.3.3 Aldosterone Concentration 
 Estrogen treatment showed a consistent suppression of plasma aldosterone across all 
groups, consistent with previous data (Macova et al., 2008). Previous research has demonstrated 
that aldosterone stimulated by dietary sodium deprivation alone is unchanged by estrogen 
treatment (Roesch et al., 2000). However, this research used a shorter time course of the sodium 
deficient diet than our protocol, which could explain the differences in results. It is possible that 
aldosterone may be decreased through suppression of the AT1 receptor, as estrogen treatment 
decreases expression of this receptor in the adrenals (Roesch et al., 2000).  
A larger response to the repeated sodium deprivation was seen in OIL-treated rats than 
EB, though this effect failed to achieve significance. This could indicate an effect of repeated 
sodium deprivation that is obscured by a large amount of variability in our data, which may have 
been due to technical challenges in the aldosterone assay or due to a relatively small number of 
samples. However, previous studies have not seen alterations in aldosterone after repeated 
furosemide deprivations (Sakai et al., 1987; Sakai et al., 1989). This study also did not see a 
difference in aldosterone between males and females. While we did not use males in our 
experiment, it would be expected that there would be differences, since our EB-treated rats had 
consistently lower aldosterone. This could be due to a difference in intact females compared to 






5.4 Behavioral and Physiological Integration 
 Taken together, the aforementioned results provide a clearer picture of the relationship 
between body fluid homeostasis and estrogen status. In Figure 19, we propose the following 
schematic to display the interrelationship between the hormones we measured and estrogen. 
Ultimately, the final result of treatment with estradiol benzoate achieved an end goal that, while 
we did not measure it, should decrease blood pressure through decreased renal sodium 
reabsorption, decreased water retention, and vasodilation. However, it still remains to be tested 
whether blood pressure is altered in female Sprague-Dawley rats during repeated episodes of 
sodium deprivation. While blood pressure can be altered with varying dietary salt in rats bred to 
be genetically prone to salt sensitivity (Fang et al., 2001; Zheng et al., 2008), less data is available 
on traditional strains such as we used, and we are not aware of any research that directly 
measured blood pressure alterations in relation to repeated episodes of sodium deprivation. 
Further research should also explore how repeated dietary sodium deprivations affect genetic 
models of hypertension and salt sensitivity, such as the Dahl salt sensitive and spontaneously 




Figure 19. Proposed mechanistic schematic. Estrogen decreases norepinephrine, which leads to vasodilation, as well 
as decreased renal sodium reabsorption. Decreases in aldosterone also affect the renal system. Estrogen also 
decreases fluid concentration consumed, which could influence vasopressin and lead to an overall reduction in water 
retention. All of these effects could be decreasing blood pressure. Additionally, unknown mechanisms lead to an 









 We also performed a semi-quantitative assessment to further examine the effects of 
estrogen and repeated dietary sodium deprivations. These are shown in Table 5 below. 
Table 5. Comparison of plasma hormone levels to sCon. We compared group means to the 
control group means (sCon OIL or EB) based on Z scores. — = <0.5 standard deviations from 
control group; ­/¯ = >0.0 to £ 1.0 standard deviations from control group; ­­/¯¯ = > 1.0 to £ 2.0 
standard deviations from control group; ­­­/¯¯¯ = > 2.0 to £ 3.0 standard deviations from 
control group; ­­­­/¯¯¯¯ = > 3.0 standard deviations from control group. 
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 This table compares rats within hormone treatment (OIL or EB). When viewed in this 
manner, it is clear that when on the sodium deficient diet, OIL-treated rats tend toward larger 
hormonal responses to the diet, as compared to sCon rats. While EB-treated rats do utilize 
compensatory mechanisms related to the sodium deficient diet, this response is not as 
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pronounced, and, in some cases, such as norepinephrine and epinephrine, largely no greater than 
the sCon rats, which were never exposed to low sodium chow.  
 The hormones we measured—norepinephrine, epinephrine, vasopressin, and 
aldosterone—do not explain the increased intake during recovery, as shown by both the data and 
Table 5. Increases in both vasopressin and aldosterone can increase sodium appetite. Yet we saw 
a sodium appetite that was increased above baseline, while these hormones were decreased. 
Therefore, it is unlikely either of these is responsible for the observed enhancement in EB-treated 
rats’ sodium appetite after sodium deprivation. The mechanisms behind this increased intake 
remain to be determined. Nonetheless, our results indicate the post-deficiency enhancement in 
sodium appetite is present after dietary sodium deprivation only in EB-treated rats, indicating that 
estrogen is critical for this effect in females. Overall, it is clear that there were changes due to 
experience with estrogen treatment, others due to experience with salt, but it seems unlikely that 
the observed hormone changes are due to experiences with repeated dietary sodium deprivation. 
Whether further deprivations may alter this conclusion remains to be examined. 
The increased salt intake occurs despite having consumed enough to restore salt lost from 
the low salt diet. This was not due to alterations in plasma sodium. Plasma sodium was no 
different in Con rats compared to NaD-, which did not obtain sodium repletion through a two-
bottle test, nor is there a difference between OIL- and EB-treated NaD- rats. Other studies have 
compared plasma sodium concentration in males and females to determine the cause of the 
increased post-depletion intake in females, and have found no difference (Sakai et al., 1989). Our 
data extend this finding to OIL- vs. EB-treated rats, meaning that plasma sodium concentration is 
not altered by ovariectomy, despite the differences in salt intake in these groups.  
Other studies have shown similar alterations in female rats’ post-deprivation intakes, 
though this research used furosemide (Chow et al., 1992; Sakai et al., 1987; Sakai et al., 1989). 
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However, our data suggest a role for estrogen in the previously seen sex differences. Our study 
isolated estrogen as influencing this phenomenon by using ovariectomized rats given EB 
treatment. Additionally, our research extended the enhanced intake to females ovariectomized 
past sexual maturity. Previous studies have not compared ovariectomized females given estrogen 
replacement with those given vehicles. However, Chow et al. (1992) did find that ovariectomized 
females given testosterone had greatly decreased salt intake. Even though our results suggest 
estrogen is influencing the response to the low salt diet, we recognize it is possible the sex 
differences present in previous studies may also be influenced by testosterone. This will require 
further study to compare the effects of estrogen and testosterone when it comes to salt intake and 
the post-deprivation enhancement observed. 
 While the changes in post-deprivation intakes are not due to differences in plasma 
sodium concentration, nor due to alterations in the measured body fluid hormones, it is possible 
there are changes in the brain which may occur both in the presence of estrogen and after a 
perceived threat to body fluid homeostasis such as dietary sodium deprivation. Studies on brain 
changes after multiple deprivations are minimal. Na et al. (2007) found increased Fos-ir 
expression in the basolateral amygdala and shell of the nucleus accumbens, areas associated with 
the mesolimbic reward system. It is possible reward may be involved, however, we provided a 
24-hour period of access to the 0.5 M NaCl prior to deprivations in an attempt to minimize 
reward responses. Regardless, the study by Na et al. was only done in males, using furosemide 
treatment, and needs to be extended to females. 
 Areas of the brain other than reward may also be involved and may be modulated by 
estrogen. Estrogen receptors, specifically ERβ, are present in the supraoptic nucleus (SON) and 
paraventricular nucleus (PVN), areas involved in release of vasopressin. We did see a significant 
difference in vasopressin levels in single vs. repeated deprivation animals, which may point to 
changes in one of these areas of the brain. The SON has been shown to have increases in Fos-ir 
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after repeated sodium deprivations (Na et al., 2007). We did find differences in vasopressin-
treated animals, but rCon were also increased, meaning this difference could have been a factor of 
age. Regardless, the fact that vasopressin was elevated could mean that the estrogen modulated 
some component of the system that could play a role in changing salt appetite.  
 Estrogen receptor alpha (ERα) is also present in the nucleus of the solitary tract (NTS) 
and area postrema (AP) (Hay et al., 2014). These areas receive gustatory input from the chorda 
tympani, as well as baroreceptor input from glossopharyngeal and vagus nerves. ERα could be 
contributing to changes in taste perception after repeated sodium deprivations, which may 
ultimately be responsible for either the decreased sodium concentration consumed, the increased 
salt intake in the Recovery period, or both. Further studies are necessary to determine any 
alterations, if any, occur in these areas of the brain.   
 
5.5 Clinical Implications 
 The low salt diet is usually one of the first line treatments for hypertension. However, it is 
clear from research that patients are often noncompliant despite interventions that attempt to 
increase compliance (Cohen et al., 1991; Pietenin et al., 1984; Staessen et al., 1988). Repeated 
dietary sodium deprivation in the rat functions as a physiological model for these specific patient 
populations who are noncompliant with their diet. Although none of the hormones we measured 
showed a definitive effect of multiple deprivations, behavior was affected by deprivations. While 
the immediate post-deprivation two-bottle tests did not have differences in salt intake between 
OIL- and EB-treated rats, EB-treated rats drank less concentrated solutions. This suggests that 
estrogen may cause less overcompensation in the immediate period following a time on the low 
salt diet. It is possible that postmenopausal women without hormone replacement therapy may 
consume higher amounts of salt when they “cheat” on their low salt diet. This phenomenon needs 
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to be verified in humans, but, if true, would require further counseling from the physician about 
the consequences of “cheating” for postmenopausal women. 
Additionally, our data in the Recovery period suggest that estrogen results in long-lasting 
increases from baseline. Based on this, we can speculate that perhaps premenopausal women may 
unintentionally consume more salt after they have previously been on the low salt diet, despite 
having already replenished their salt after the time on the diet. For this reason, it may also be 
important to counsel premenopausal women on the consequences of “cheating” on the low salt 
diet, albeit for different reasons than postmenopausal women. Consuming more salt in the 
unstimulated period after the low salt diet may exacerbate hypertension in those who are salt 
sensitive. This may also apply to postmenopausal women on hormone replacement therapy, 
though the clinical applications in both populations will need to be explored further in future 
research. 
It is already known that consuming salt can exacerbate hypertension and congestive heart 
failure, so individuals either with endogenous estrogen or on hormone replacement therapy 
should be aware of the possibility of greater salt cravings after exposure to the diet. It remains to 
be seen if estrogen status relates to greater incidence of exacerbations of salt sensitive 
hypertension and heart failure complications, but it is clear that this area must be explored further 
to better serve patients and provide appropriate education related to the low salt diet.  
Our current study focused on females, which is an often overlooked population. This data 
and model could also be instructive in terms of broader applications. While we focused on the 
effects of estrogen, it also remains to be seen what effects are seen with repeated dietary sodium 
deprivations in males as well. While these two possible changes—increased intake immediately 
after deprivation in postmenopausal women, and increased intake for long periods after 
deprivation in premenopausal women—may not be a problem for many women, some may be 
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salt sensitive, and experience fluctuations in blood pressure with increasing salt consumption. 
Further research is needed on best methods for increasing compliance of this difficult diet, and 
how the animal studies apply to humans. Given the prevalence of salt in the American diet, it is 
imperative that this research expand so that physicians may counsel women on the importance of 
maintaining their diet, not just due to short term alterations, but because of possible long term 
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